ORIGINAL ARTICLE

Laparoscopic versus Robotic Peripheral Pancreatectomy: A Systematic Review and Meta-analysis

Georgios Mavrovounis, Alexandros Diamantis, Konstantinos Perivoliotis, Dimitrios Symeonidis, Georgios Volakakis, Konstantinos Tepetes

Department of General Surgery, University Hospital of Larissa, Mezourlo, Larissa, Thessaly, 41110, Greece

Summary

Purpose: The current systematic review and meta-analysis aimed to compare Laparoscopic Distal Pancreatectomy (LPD) with Robotic Distal Pancreatectomy (RDP) in terms of length of hospital stay (LOS), perioperative, postoperative and economic parameters.

Methods: A systematic review of the literature was undertaken and data from studies fulfilling the predetermined inclusion criteria were extracted. Meta-analyses were performed to combine the results of various studies in the forms of Weighted Mean Difference (WMD), Odds Ratio (OR) and Risk Difference (RD), as appropriate.

Results: A significantly lower LOS (WMD:0.75, 95%CI:0.17-1.33) and longer operative duration (WMD:-28.29, 95%CI:-49.98--6.6) for the RDP group was found. The rate of open conversion was higher in the LDP group (OR:2.38, 95%CI:1.75-3.22), while the rate of spleen preservation was lower (OR:0.49, 95%CI:0.31-0.79). No significant differ-

ence was noted in the intraoperative blood loss (WMD:34, 95%CI:-10.28-78.29), postoperative blood transfusion (OR:0.99, 95%CI:0.66-1.49) and overall morbidity analyses (OR:1.08, 95%CI:0.88-1.32). A significantly higher yield of lymph nodes was achieved in the RDP group (WMD:-2.09, 95%CI:-4.17--0.01), while no differences were found when positive resection margins (RD:0.02, 95%CI:-0.02-0.07) and specimen length (WMD:0.08, 95%CI:0.42-0.58) were considered. Finally, RDP was associated with significantly higher operative (WMD:-2733.42, 95%CI:-4189.77--1277.08) and total (WMD:-3799.68, 95%CI: -4438.39--3160.98) costs.

Conclusion: RDP seems to be a viable option for both benign and malignant pancreatic disorders, although there are concerns regarding economic parameters. Large randomized controlled trials will shed more light on the subject.

Key words: Distal Pancreatectomy; Laparoscopic Surgery; Pancreatic Cancer; Robotic Surgery

Introduction

Distal pancreatic resection is utilized for the surgical management of inflammatory or neoplastic pancreatic disorders located in the body and tail of the pancreas [1].

Laparoscopic distal pancreatectomy (LDP) is a relatively new procedure in the general surgeon's armamentarium. In fact, it was only in 1996 when Cuschieri et al and Gagner et al reported the first two case series of patients with pancreatic pathology (chronic pancreatitis and insulinomas, respectively) treated with a LDP [2,3]. The experience of pancreatectomy (RDP) approach. Performed for the

surgeons with the laparoscopic technique has been increasing since, allowing for the achievement of similar results when comparing LDP with open pancreatectomy, for both benign and neoplastic disorders [4,5]. Not only does laparoscopy allows for similar outcomes but it also results in smaller surgical incisions and faster recovery for the patients [6].

The rise of robotic applications in surgery resulted in the development of the robotic distal

Corresponding author: Alexandros Diamantis, MD, MSc. Department of General Surgery, University Hospital of Larissa, Mezourlo, Larissa, Thessaly, 41110, Greece.

Tel: +30 6948594006, Fax: +30 2413-501559, Email: alexandrosdoc@gmail.com Received: 05/04/2020; Accepted: 03/05/2020

This work by JBUON is licensed under a Creative Commons Attribution 4.0 International License.

first time by Melvin et al in 2003 for a neuroendocrine tumor [7], RDP is the most contemporary technique available for the surgical management of pancreatic diseases [8]. When the robotic approach to the pancreas was introduced, it was believed that it would help minimize the ergonomic issues faced by surgeons using laparoscopic tools, thus, resulting in better outcomes [9]. Even though the perceived ergonomic advantages of the robot indeed transpired into everyday surgical practice, the long-awaited oncological and surgical benefits for the patients were not observed and the critics of RDP argue that robotic procedures are lengthier and more costly [9,10].

Although surgical and technological advancements have made distal pancreatectomy a much safer procedure than it was before [11,12], both LDP and RDP are still associated with several complications [13]. Particularly, postoperative pancreatic fistula (POPF), spleen sacrifice, intraoperative and postoperative blood loss and surgical infections increase the overall morbidity and mortality of the patients [13].

Evidently, even though minimally invasive procedures such as LDP and RDP are both comparable to or even better than the open approach for pancreatic lesions, it is still debatable which one, if any, results in more favorable outcomes for the patients. The aim of the current systematic review and meta-analysis is to compare the LDP and RDP approaches in terms of various parameters spanning the spectrum of perioperative and postoperative care and cost-effectiveness.

Methods

Literature search

In order to retrieve the eligible studies, a systematic literature search in the electronic databases (Medline, Web of Science and Scopus) was performed. The last literature screening date was 10 September 2018.

The following Boolean search algorithm was implemented: (Distal pancreatectomy OR left pancreatectomy OR peripheral pancreatic resection) AND (laparoscopic OR laparoscopy OR robotic OR robot).

Eligibility criteria

As eligible studies were considered all retrospective and prospective human studies, comparing LDP and RDP, in terms of malignant or benign primary diseases, whose outcomes of interest were provided in English and were retrievable.

Exclusion criteria for this meta-analysis included: 1) non-human studies, 2) studies not reported in English, 3) with no outcome of interest, 4) with no comparison group, 5) irretrievable outcome data and 6) manuscripts in the form of editorials, letters, conference abstracts and expert opinions.

Study selection and data collection

After removing the duplicate entries, the titles and abstracts of the remaining studies were screened. The next step included a full text review of the articles in order to assess consistency with the eligibility criteria. Electronic database screening, study selection, data extraction and quality assessment was performed blindly and in duplicate by two independent researchers (DA and PK). In case of a discrepancy, mutual revision and discussion was applied. If the disagreement was not resolved, the opinion of a third investigator was considered (TK).

Endpoints and definitions

The primary endpoint of the present study was the pooled mean difference of the length of hospital stay (LOS) in patients who were submitted to either, laparo-




Figure 1. Flow diagram for study selection according to PRISMA guidelines.

Table 1. Included studies								
First author – YOP (Country)	Study Type (Single Multiple Centers)	Group	Sample	Age	Sex (Male Female)	BMI (kg/m2)	Number of Surgeons (MIS Experience)	Follow-up Period
Fisher et al. – 2018 (USA)	Retrospective (Single)	LDP	146	58 (10.37)	66 80	n/a	n/a (n/a)	n/a
		RDP	53	59 (10.37)	20 33			
Raoof et al. – 2018 (USA)	Retrospective (Multiple)	LDP	605	138 (<65)	322 283	n/a	n/a (n/a)	Median: 25 months
		RADP	66	23 (<65)	45 54			
Souche et al2018 (France)	Prospective (Single)	LDP	23	66 (9.75)	9 14	25(3.5)	n/a (Yes)	n/a
		RDP	15	57 (9.5)	3 12	23(3)		
Goh et al. – 2017 (Singapore)	Retrospective (Single)	LDP	31	56 (13.25)	18 13	23.9(4.3)	8 (n/a)	90 days
		RADP	8	57 (11.75)	2 6	27.6(2.3)	3 (n/a)	
Ielpo et al. – 2017 (Spain)	Retrospective (Single)	LDP	26	61.3 (9.5)	17 9	24.5(3.37)	Multiple (Yes)	n/a
		RDP	28	59.7 (9.5)	16 12	24.1(3.25)		
Liu et al. – 2017 (China)	Retrospective (Single)	LDP	102	49.6 (15.2)	47 55	n/a	3 (Yes)	n/a
		RDP	102	48.1 (15.5)	34 68			
Xourafas et al. – 2017 (USA)	Retrospective (Multiple)	LDP	694	62 (17.5)	275 419	28.4(10.5)	n/a (n/a)	n/a
		RDP	200	62 (16.5)	83 117	28.8(10)		
Zhang et al. – 2017 (China)	Retrospective (Single)	LDP	31	48.7 (12.3)	12 19	23.3(2.7)	n/a (n/a)	Median: 23 months
		RDP	43	47.9 (10.5)	20 23	23.9(3.2)		Median: 16 months
Eckhardt et al. – 2016 (Germany)	Retrospective (Single)	LDP	29	59 (17)	12 17	26.99(4.35)	1 (n/a)	Median: 30.5 months
		RADP	12	48.5 (11.75)	4 8	23(3.62)		Median: 6 months
Morelli et al. – 2016 (Italy)	Retrospective (Single)	LDP	15	49.3 (17.1)	2 13	26.5(1.9)	2 (Yes)	>1 year
		RADP	15	58.2 (13.7)	6 9	26.4(3.1)		
Adam et al. – 2015 (USA)	Retrospective (Multiple)	LDP	474	64 (13)	248 226	n/a	n/a (n/a)	n/a
		RDP	61	65 (14)	28 33			
Butturini et al. – 2015 (Italy)	Prospective (Single)	LDP	21	55 (12.7)	6 15	24.19	Multiple (n/a)	Median: 15 months
		RDP	22	54 (12.7)	5 17	25.33		Median: 10.5 months
Chen et al. – 2015 (China)	Prospective (Single)	LDP	50	56.5 (15)	18 32	24.6(3)	2 (Yes)	Median: 27 months
		RADP	69	56.2 (13.3)	23 46	24.6(2.8)		
Lai et al2015 (China)	Retrospective (Single)	LDP	18	63.2 (17.9)	4 14	25.7(2.7)	n/a (n/a)	Mean: 113.5 months
		RDP	17	61.2 (10.4)	10 7	24.1(2.3)		Mean: 27.4 months
Lee et al. – 2015 (USA)	Retrospective (Single)	LDP	131	58 (15)	57 74	28.2	4 (Yes)	Median: 13 months
		RDP	37	58 (11.1)	10 27	28.7		
Continued on the next page								

Laparoscopic vs robotic pancreatectomy

JBUON 2020; 25(5): 2458

First author – YOP (Country)	Study Type (Single Multiple Centers)	Group	Sample	Age	Sex (Male Female)	BMI (kg/m2)	Number of Surgeons (MIS Experience)	Follow-up Period
Balzano et al. – 2014 (Italy)	Retrospective (Multiple)	LDP RADP	140 31	n/a	n a	n/a	n/a (n/a)	n/a
Duran et al. – 2014 (Spain)	Retrospective (Single)	LDP RDP	18 16	58.3 (10) 61 (11.6)	9 9 7 7	n/a	Multiple (Yes)	n/a
Ito et al. – 2014 (Japan)	Retrospective (Single)	LDP RDP	10 4	52.4 52.7	n a 1 3	n/a	n/a (n/a)	n/a
Benizri et al. – 2013 (France)	Retrospective (Single)	LDP RADP	23 11	52.3 (14.7) 50.1 (21.1)	10 13 3 8	26.5(4.7) 25.6(5.8)	2 (Yes)	n/a
Daouadi et al. – 2013 (USA)	Retrospective (Single)	LDP RADP	94 30	59 (16) 59 (13)	10 20 33 61	29(7.1) 27.9(5.1)	7 (Yes)	n/a
Kang et al. – 2010 (S. Korea)	Retrospective (Single)	LDP RADP	25 20	56.5 (13.9) 44.5 (15.9)	11 14 8 12	23.4 (2.6) 24.2 (2.9)	n/a (n/a)	n/a
Waters et al. – 2010 (USA)	Prospective (Single)	LDP RDP	18 17	59 64	9 9 6 11	n/a	n/a (n/a)	n/a
Abbreviations: YOP - Year of Publication, LDP/RDP/RDP - Laparoscopic/Robotic/Robot-Assisted Distal Pancreatectomy, BMI - Body Mass Index, MIS - Minimally Invasive Surgery, n/a - not available	tion. LDP/RDP/RADP – Laparoscot	oic/Robotic/Rc	bot-Assisted I	Distal Pancreatecto	mv. BMI – Bodv Ma	ss Index. MIS – N	Ainimally Invasive Surgery.	n/a – not available

scopic (LDP), or robotic distal pancreatectomy (RDP) for benign, or malignant diseases.

The secondary outcomes included comparisons between the two techniques in terms of perioperative outcomes, such as operative duration, intraoperative blood loss and transfusion frequency, open conversion and spleen preservation rates. Furthermore, the postoperative complications rates (e.g. postoperative pancreatic fistula, severe complications, fluid collections, postoperative hemorrhage, surgical site infection, reoperation, readmission, mortality and overall complications) of LDP and RDP were also compared.

More specifically, postoperative pancreatic fistula (POPF) was categorized on the basis of the ISGPF classification [14]. As severe complication was considered any postoperative adverse event graded ≥III according to Clavien-Dindo classification [15].

Analysis in terms of oncological outcomes (e.g. positive resection margins, extracted lymph nodes and specimen length) was also implemented. Finally, LDP and RDP were also compared concerning the operative and overall costs. Data regarding the above mentioned endpoint were converted to Euro based on the current currency rate.

Quality scoring and publication bias

The quality and methodological evaluation of the eligible studies included the assessment on the basis of Newcastle-Ottawa Scale (NOS) [16]. Rating based on this tool was performed in terms of selection and comparability of the study groups and the confirmation of exposure. Each trial was appointed a score ranging from 0 to 9. Cohen's K statistic was also calculated.

In order to determine the possible presence of publication bias, the funnel plot of the primary endpoint was visually inspected. Furthermore, Egger's test was also calculated on the basis of the primary outcome.

Statistics

Data analysis and statistical computations were performed using the IBM SPSS version 23 and RevMan version 5.3. The endpoints of the present meta-analysis were presented in the form of Weighted Mean Difference (WMD) and Odds Ratio (OR) or Risk Difference (RD), for continuous and dichotomous variables, respectively. The results of the analyses were opposed with the corresponding 95% Confidence Intervals (95% CI).

In case that an eligible trial did not provide the mean or the Standard Deviation (SD) of a continuous variable, then they were calculated from the respective median and range, according to the formula described by Hozo et al [17].

For dichotomous variables, the statistical method applied was the Mantel-Haenszel (MH) and for continuous variables the Inverse Variance (IV). Both Fixed Effects (FE) and Random Effects (RE) models were estimated. The model that was finally reported was based on the Cochran Q test. More specifically, if the heterogeneity levels were significant (Q test P<0.1), then the RE model was applied. Heterogeneity levels were also quantified through the calculation of I². Statistical significance was considered at the level of P<0.05.

First Author	Group					Dia	ignosis	;				ASA	Grade		Previous Operation
		PDAC	SCT	МСТ	IPMT	NET	SPT	Pancreatitis Pseudocyst	IPAS	Benign Stricture	Ι	II	III	IV	-
Fisher et al.	LDP				D	ata no	t avai	lable							
	RDP														
Raoof et al.	LDP RADP				D	ata no	ot avai	labe							
			1	7	7	0	0		1	/-	~	10	0	0	r
Souche et al.	LDP RDP	n/a	1 1	3 2	7 2	8 8	0 1	n/a	1 0	n/a	5 8	18 7	0 0	0 0	5 2
Cob at al	LDP	4	1 7	2 3	2 2	° 15	5	1		m /a	° 31	0			10
Goh et al.		4	/	2	2	15	Э	1	n/a	n/a			0	0	
	RADP	17	n	C	7	7	0	1	0	0	7	1	0	0	1
Ielpo et al.	LDP	13	2	2	3	7	0	1	0	0	3	20	3	0	n/a
T	RDP	15 25	1	1	4	6	0	2	0	0	2	23	3	0	
Liu et al.	LDP	25	16	20	7	15	15	4	4	4	8	91 00	3	0	n/a
Name (and all	RDP	26	16	17	6	16	16	5	5	5	10	90 275	2	0 25	
Xourafas et al.	LDP				D	ata no	t avai	lable			13	235	421	25	n/a
-	RDP		-		•		•	0		0	2	63	126	9	,
Zhang et al.	LDP	0	0	0	0	31	0	0	0	0	22	9	0	0	n/a
	RDP	0	0	0	0	43	0	0	0	0	32	11	0	0	
Eckhardt et al.	LDP	1	7	5	11	0	4	0	0		Dat	ta not	availa	able	n/a
	RADP	0	3	3	5	0	0	0	0						
Morelli et al.	LDP				D	ata no	t avai	lable					0.46)		5
	RADP											2.4(0.51)		5
Adam et al.	LDP	234	n/a	n/a	n/a	197	n/a	n/a	n/a	n/a	Dat	ta not	availa	able	n/a
	RDP	33				24									
Butturini et al.	LDP	2	2	7		9	1	n/a	0	n/a	5	16	0	0	13
	RDP	3	0	6		8	3		1		3	18	1	0	15
Chen et al.	LDP	9	n/a	16	5	3	8	n/a	n/a	n/a	5	43	1	0	n/a
	RADP	15		26	6	3	10				7	59	3	0	
Lai et al.	LDP	2	6	4	0	2	1	3	n/a	n/a	4	14	0	0	n/a
	RDP	3	6	2	1	4	0	0			6	11	0	0	
Lee et al.	LDP	19	n/a	16	18	41	7	n/a	n/a	n/a			3		n/a
	RDP	4		6	4	8	2					2	.5		
Balzano et al.	LDP	29	22	34	13	49	n/a	1	n/a	n/a	Dat	a not	availa	able	n/a
	RADP														
Duran et al.	LDP	8	n/a	n/a	0	5	n/a	2	n/a	n/a	4	11	3	0	n/a
	RDP	9			2	4		0			0	16	0	0	
Ito et al.	LDP	0	1	1	0	2	3	0	0	0	-	-	-	-	
	RDP	-	-	-		- Data no			-	-	Da	ta not	avail	abe	n/a
Benizri et al.	LDP	3	3	4	3	7	2	1	0	0	20	3	0		10
	RADP	0	2	2	1	2	3	0	0	0	10	1	0		6
Daouadi et al.	LDP	14		30	11	21	6	n/a	n/a	n/a	42	*	51		48
zaouuui et ul.	RADP	13		4	5	9	0	11/ U	11/ U	11/ U	11		19		22
Kang et al.	LDP	n/a	3	4	10	9 3	4	1	1	1		a not	availa	hle	n/a
nung et al.	RADP	11/a	4	5	2	3	4	1	1	0	Dai		avana .9	IDIC	n/a
Waters at al	LDP	2	4	3	2	5							.9 .8		11/ a
Waters et al.	ъυР	2	4	C	4	5	n/a	n/a	n/a	n/a		2	.0		

Table 2. Patient characteristics

LDP/RDP/RADP – Laparoscopic/Robotic/Robot-Assisted Distal Pancreatectomy, n/a – not available, PDAC - Pancreatic Ductal Adenocarcinoma, SCT – Serous Cystadenoma, MCT – Mucinous Cystadenoma, IPMT – Intraductal Papillary Mucinous Neoplasms, NET – Neuroendocrine Tumors, SPT – Solid Pseudopapillary Tumors,IPAS – Intrapancreatic Accessory Spleen , ASA – American Society of Anesthesiologists

Study protocol

This systematic review and meta-analysis was conducted on the basis of the Cochrane Handbook for Systematic Reviews of Interventions and the PRISMA guidelines [18].

Results

Study selection

Electronic database search resulted in the retrieval of 2701 records (Figure 1). More specifically, 918 entries were identified through Medline, 1003 through Web of Science and 780 through Scopus. After the removal of 1329 duplicate records, 1372 titles and abstracts were screened. During this phase of literature screening 1339 studies (15 comments, conference abstracts, or letters, 22 non-human studies, 46 studies with no comparison group, 159 reviews or meta-analyses and 1097 irrelevant records) were excluded. Full text assessment of the remaining 33 articles identified 3 studies that did not provide adequate outcome data, 1 study without a comparison group and 7 irrelevant records. More specifically, from this group, 2 studies [19,20] that compared single site laparoscopic or robotic distal pancreatectomy were excluded. Finally 22 studies were included in the qualitative and quantitative analysis [21].

Study characteristics

The characteristics of the included studies are summarized in Table 1 (Supplementary Material). Publication year ranged from 2010 to 2018. In total, 18 [21-38] and 4 [39-42] studies had a retrospective and a prospective study design, respectively. Nine studies [23-25,27,29,31,35,36,40] reported the application of a robotic assisted operative technique. Only 4 studies [22,23,36,37] were conducted in more than one institutions. Furthermore, gender, age and BMI allocation between the study subgroups is also displayed in Table 1. Multiple (≥ 3) operating surgeons were reported in 7 studies [21,25,26,29,33,34,39]. Experience in minimally invasive techniques was documented in 9 studies [21,24-26,33-35,40,41]. Mean postoperative follow up period spanned from 3 months [29] up to 113 months [32].

Considering the underlying pathology, the neuroendocrine tumors (NET), was the most frequent diagnosis, followed by the adenocarcinoma (PDAC) of the pancreas (Table 2 Supplementary Material). Other diagnoses included the mucinous cystadenoma (MCT), serous cystadenoma (SCT), intraductal papillary mucinous neoplasms (IPMT) and solid pseudopapillary tumors (SPT). Benign patholoTumor characteristics

ň

Table

First Author	Group	Group Tumor Size Tumor Site	Tumor Site		Tumor		Nodes		Grade		Neoai	Neoadjuvant		Adjuvant	
			Body Tail	1	2 3	4	0 1	Low	Intermediate	High	Chemotherapy	Chemoradiation	Chemotherapy	0 1 Low Intermediate High Chemotherapy Chemoradiation Chemotherapy Chemoradiation Radiation	Radiation
Fisher et al.	LDP	n/a	n/a		n/a		n/a		n/a			n/a			
	RDP														
Raoof et al.	LDP	3.7(1.7)	182 423 66 106 406	66	106 406	12	279 301	1 62	300	189	16	10	221	124	11
	RDP	3.5(1.5)	29 70 12	12	22 64	0	45 45	5 15	49	25	7	2	40	18	1
Souche et al.	LDP	3.5(1.5)	n/a		n/a		n/a		n/a		и	n/a		n/a	
	RDP	2.8(1.3)													
Goh et al.	LDP	2.5(1.5)	n/a		n/a		n/a		n/a		и	n/a		n/a	
	RADP	3(1.4)													
Ielpo et al.	LDP	3.83(2)	n/a		n/a		n/a		n/a		6			n/a	
	RDP	3.54(1.95)									8				
Liu et al.	LDP	4.56(3.2)	n/a		n/a		n/a		n/a		n/a	2		n/a	
	RDP	4.2(1.44)													
Continued on the next page	next page														

Antication Bady Ted 1 2 3 4 1 bot Intermediates Figs 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 1 2 1 2 1 2 1 <th1< th=""> 1 2 <t< th=""><th>First Author</th><th>Group</th><th>Group Tumor Size Tumor Site</th><th>Tumor Site</th><th></th><th>Tumor</th><th></th><th>Nodes</th><th></th><th>Grade</th><th></th><th>Neoa</th><th>Neoadjuvant</th><th></th><th>Adjuvant</th><th></th></t<></th1<>	First Author	Group	Group Tumor Size Tumor Site	Tumor Site		Tumor		Nodes		Grade		Neoa	Neoadjuvant		Adjuvant	
				Body Tail	1				Low	Intermediate					Chemoradiation	Radiation
	Kourafas et al.	LDP	n/a	n/a		r>3 n=136	р П П			n/a		8	2		n/a	
		RDP				T>3 n=46		29				17	7			
RDP 16(0.68) 13 50 7 1 12 10 <	Zhang et al.	LDP	1.6(0.74)			n/a		n/a	24	2	2	[a/a		n/a	
I. LDP 205(27) 11 18 n/a n/a <td></td> <td>RDP</td> <td>1.6(0.88)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>35</td> <td>7</td> <td>1</td> <td></td> <td></td> <td></td> <td></td> <td></td>		RDP	1.6(0.88)						35	7	1					
RADP 2.1(0.65) 4 8 N DP na <	Eckhardt et al.	LDP	2.05(2.7)			n/a		n/a		n/a			n/a		n/a	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		RADP	2.1(0.85)													
	Aorelli et al.	LDP	n/a	n/a		n/a		n/a		n/a		[a/a		n/a	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		RADP	3.6(2)	115 359		n/a		n/a		n/a		-	a/a		n/a	
	vdam et al.	LDP	3.8(2.2)													
II IDP 255(2125) RDP 55(1.125) i		RDP	3.5(1.5)	n/a		n/a		n/a		n/a		[a/a		n/a	
RDP Normalize Normalicit Normalize Nor	sutturini et al.		2.55(2.125)													
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		RDP														
	hen et al.	LDP	3.5(1.7)		n/a	7	ı/a	n/a		n/a		[a/a	6	n/a	n/a
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		RADP	3.5(1.6)											14		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	ai et al.	LDP	n/a	n/a		n/a		n/a		n/a		-	n/a		n/a	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		RDP														
RDP Na n/a n/a n/a n/a 1. LDP 3(1.3) n/a n/a n/a n/a RADP 413(2.34) n/a n/a n/a n/a LDP 413(2.34) n/a n/a n/a n/a 8 RDP 2.78(1.63) n/a n/a n/a 8 9 LDP n/a n/a n/a n/a 9 9 RDP 2.7(1.3) n/a n/a n/a 10/a 10/a RDP 2.7(1.3) n/a n/a 10/a 10/a 10/a LDP 2.7(1.3) n/a n/a 10/a 10/a 10/a RDP 2.7(1.3) n/a n/a 10/a 10/a 10/a RDP 2.7(1.3) n/a n/a 10/a 10/a 10/a RDP 2.7(1.4) n/a 10/a 10/a 10/a 10/a	ee et al.	LDP	n/a	n/a		n/a		n/a		n/a			n/a		n/a	
I. LDP 3(1.8) n/a n/a n/a n/a RADF <		RDP														
RADP 8 LDP 4.13(2.34) n/a n/a 8 RDP 2.78(1.65) 9 9 LDP 1/a n/a n/a 1/a LDP 2.78(1.65) n/a n/a 1/a LDP 2.78(1.65) n/a n/a 1/a LDP 2.78(1.65) n/a n/a 1/a RDP 2.7(1.3) n/a n/a 1/a RDP 3.6(2.5) n/a n/a 1/a RADP 3.6(2.5) n/a n/a 1/a LDP 2.7(1.3) n/a n/a 1/a RADP 2.6(1.4) n/a n/a 1/a LDP 3.6(1.4) n/a n/a 1/a RDP 3.6(1.4) n	alzano et al.	LDP	3(1.8)	n/a		n/a		n/a		n/a			n/a		n/a	
LDP 4.15(2.34) n/a n/a n/a n/a a RDP 2.78(1.63) n/a n/a n/a 9 LDP n/a n/a n/a n/a n/a RDP 2.78(1.63) n/a n/a n/a n/a RDP n/a n/a n/a n/a n/a RDP 2.7(1.5) n/a n/a n/a n/a RDP 2.7(1.5) n/a n/a n/a n/a RDP 2.7(1.5) n/a n/a n/a n/a RDP 2.6(1.4) n/a n/a n/a n/a LDP 2.0(1.4) n/a n/a n/a n/a LDP 3.0(1.4) n/a n/a n/a n/a RADP 2.0(1.4) n/a n/a n/a n/a RADP 3.5(1.3) n/a n/a n/a n/a RADP 3.5(1.3) n/a n/a n/a n/a RADP 3.5(1.3) n/a n/a <td></td> <td>RADP</td> <td></td>		RADP														
RDP 2.78(1.63) 9 LDP n/a n/a n/a n/a RDP 2.7(1.3) n/a n/a n/a RDP 2.7(1.3) n/a n/a n/a IDP 2.7(1.3) n/a n/a n/a RDP 3.6(2.5) n/a n/a n/a RDP 2.9(1.9) n/a n/a n/a RDP 2.9(1.4) n/a n/a n/a RDP 2.6(1.4) n/a n/a n/a RDP 2.6(1.4) n/a n/a n/a LDP 3.0(1.4) n/a n/a n/a LDP 3.0(1.4) n/a n/a n/a RADP 2.6(1.3) n/a n/a n/a LDP 3.5(1.3) n/a n/a n/a RDP 2.5(1.3) n/a n/a n/a RDP 2.1) n/a n/a n/a RDP 2.1 n/a n/a n/a	uran et al.	LDP	4.13(2.34)	n/a		n/a		n/a		n/a		8			n/a	
LDP n/a n/a n/a n/a n/a RDP 2.7(1.3) n/a n/a n/a n/a RDP 2.7(1.3) n/a n/a n/a n/a I. LDP 2.7(1.3) n/a n/a n/a n/a I. LDP 2.9(1.9) n/a n/a n/a n/a RADP 2.6(1.4) n/a n/a n/a n/a RADP 2.6(1.4) n/a n/a n/a n/a LDP 2.0(1.4) n/a n/a n/a n/a LDP 3.0(1.4) n/a n/a n/a n/a RDP 3.5(1.5) n/a n/a n/a n/a LDP 4(3) n/a n/a n/a n/a RDP 2.1.5) n/a n/a n/a n/a RDP 2.1.5) n/a n/a n/a n/a RDP 2.1.5) n/a n/a n/a n/a RDP 2.1.5 n/a n/a n/a		RDP	2.78(1.63)									6				
RDP n/a n/a n/a n/a RADP 3.6(2.5) n/a n/a n/a RADP 3.6(1.9) n/a n/a n/a I. LDP 2.9(1.9) n/a n/a RADP 2.6(1.4) n/a n/a n/a RADP 2.6(1.4) n/a n/a n/a RADP 3.0(1.4) n/a n/a n/a RADP 3.5(1.5) n/a n/a n/a RADP 3.5(1.3) n/a n/a n/a RDP 3.5(1.3) n/a n/a n/a RDP 2.5(1.3) n/a n/a n/a	to et al.	LDP	n/a	n/a		n/a		n/a		n/a		[n/a		n/a	
LDP 2.7(1.3) n/a n/a n/a n/a RADP 3.6(2.5) 1. LDP 2.9(1.9) n/a n/a n/a RADP 2.6(1.4) n/a n/a n/a RADP 2.6(1.4) n/a n/a n/a RADP 2.6(1.4) n/a n/a n/a		RDP														
RADP 3.6(2.5) 1. LDP 2.9(1.9) n/a n/a RADP 2.9(1.4) n/a n/a n/a RADP 2.6(1.4) n/a n/a n/a LDP 3.0 (1.4) n/a n/a n/a RADP 3.6 (1.3) 1/a 1/a LDP 3.0 (1.4) n/a n/a n/a RADP 3.5 (1.3) 1/a 1/a RDP 3.5 (1.3) 1/a 1/a LDP 4(3) n/a n/a n/a RDP 2.1) 2.1 1/a 1/a	enizri et al.	LDP	2.7(1.3)	n/a		n/a		n/a		n/a		-	n/a		n/a	
I. LDP 2.9(1.9) n/a n/a n/a RADP 2.6(1.4) n/a n/a n/a LDP 3.0 (1.4) n/a n/a n/a LDP 3.0 (1.4) n/a n/a n/a RADP 5.5 (1.5) LDP 4.3) n/a n/a n/a RDP 2.1)		RADP	3.6(2.5)													
RADP 2.6(1.4) n/a n/a n/a LDP 5.0 (1.4) n/a n/a n/a RADP 3.5 (1.3) LDP 4(3) n/a n/a n/a RDP 2(1)	aouadi et al.	LDP	2.9(1.9)	n/a		n/a		n/a		n/a		-	a/a		n/a	
LDP 3.0 (1.4) n/a n/a n/a RADP 3.5 (1.3) 1.13 LDP 4(3) n/a n/a RDP 2(1)		RADP	2.6(1.4)													
RADP 3.5 (1.3) LDP 4(3) n/a n/a RDP 2(1) n/a n/a	kang et al.	LDP	3.0 (1.4)	n/a		n/a		n/a		n/a			n/a		n/a	
LDP 4(3) n/a n/a n/a n/a n/a RDP 2(1)		RADP	3.5 (1.3)													
	Vaters et al.	LDP	4(3)	n/a		n/a		n/a		n/a		-	n/a		n/a	
		RDP	2(1)													

Laparoscopic vs robotic pancreatectomy

2462

First Author	Group	Stump	Transection	Drain	Trocars
Fisher et al.	LDP		n/a		
	RDP				
Raoof et al.	LDP		n/a		
	RADP				
Souche et al.	LDP	stapler & glue	harmonic	yes	n/a
	RDP	stapler & glue	electrohook and bipolar	yes	
Goh et al.	LDP		n/a		
	RADP				
Ielpo et al.	LDP	stapler	energy devices	n/a	5
	RDP	stapler	energy devices		5
Liu et al.	LDP	stapler	energy devices	n/a	4
	RDP	stapler	n/a		5
Xourafas et al.	LDP	n/a	n/a	82	n/a
	RDP			16	
Zhang et al.	LDP	stapler	n/a	yes	4
	RDP	stapler		yes	5
Eckhardt et al.	LDP	stapler or Tachosil	harmonic, electrohook and vascular clips	yes	4
	RADP	stapler or Tachosil	harmonic, electrohook and vascular clips	yes	5
Morelli et al.	LDP	stapler & oversewn	electrocautery	yes	4 or 5
	RADP	stapler & oversewn	monopolar scissors	yes	5
Adam et al.	LDP		n/a		
	RDP				
Butturini et al.	LDP	stapler	energy devices	yes	4
	RDP	stapler	energy devices	yes	5
Chen et al.	LDP	n/a	n/a	yes	n/a
	RADP			yes	
Lai et al.	LDP	stapler & oversewn	energy devices	n/a	6
	RDP	stapler & oversewn	monopolar scissors		5
Lee et al.	LDP	stapler	energy devices	surgeon's preference	4 or 5
	RDP	stapler	energy devices		4 or 5
Balzano et al.	LDP	stapler & oversewn or ultrasonic devises or patch	n/a	n/a	n/a
	RADP				
Duran et al.	LDP		n/a		
	RDP				
Ito et al.	LDP	stapler	esulon g	n/a	5
	RDP	n/a	esulon g		n/a
Benizri et al.	LDP	stapler	energy devices	n/a	5(0.5)
	RADP	stapler	energy devices		6(0.5)
Daouadi et al.	LDP	stapler & oversewn	n/a	n/a	n/a
	RADP	stapler & oversewn			
Kang et al.	LDP		n/a		
	RADP				
Waters et al.	LDP	stapler or oversewn	n/a	n/a	4 or 5
	RDP	stapler or oversewn			5

Table 4. Operative characteristics

gies such as pancreatitis, pseudocysts, accessory spleens and benign strictures were also recorded. Moreover, Table 2, displays the ASA grading of the included patients. In total, 142 patients had been submitted to previous abdominal operations.

Mean tumor size reported in the two subgroups ranged from 1.6 cm [38] up to 4.56 cm [34] (Table 3 Supplementary Material). Moreover, 458 and 1015 tumors were located in the pancreatic body and tail, respectively. The stage and the histological grade of the malignant pathologies are also provided in Table 3. Details regarding the status of the neoadjuvant or adjuvant treatment of the patients were reported in only 2 studies [36,40]. Finally, details concerning

the operative technique, such as the closure of the pancreatic stump, the transection method, the use of drain and the number of trocars are summarized in Table 4 (Supplementary Material).

Quality of studies

Table 5 (Supplementary Material), summarizes the methodological and quality evaluation of the included studies on the basis of the NOS scale. Although the overall score ranged from 2 to 7 stars, the quality level of the majority of the studies was considered to be in an adequate level. Interrater agreement was estimated to be in a more than adequate level (Cohen's k statistic: 95.5%, p<0.0001).

		LDP			RDP			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Adam et al.	6	4	474	8	10	61	3.6%	-2.00 [-4.54, 0.54]	
Benizri et al.	9	10.5	23	10	4.25	11	1.2%	-1.00 [-5.97, 3.97]	
Butturini et al.	7	7.5	21	7	6	22	1.7%	0.00 [-4.07, 4.07]	
Chen et al.	14.7	8.4	50	11.6	6.6	69	3.1%	3.10 [0.30, 5.90]	_ _ _
Daouadi et al.	7.1	4	94	6.1	1.7	30	8.6%	1.00 [-0.01, 2.01]	-
Duran et al.	19.16	15	18	8.87	1.45	16	0.7%	10.29 [3.32, 17.26]	
Eckhardt et al.	13	6.75	29	10.5	3	12	2.8%	2.50 [-0.49, 5.49]	<u>+</u>
Fisher et al.	4	2.2	146	5	1.48	53	10.6%	-1.00 [-1.53, -0.47]	*
Goh et al.	6	2.25	31	6	2.5	8	5.1%	0.00 [-1.90, 1.90]	- - -
lelpo et al.	13.1	8.25	26	8.9	3.25	28	2.3%	4.20 [0.81, 7.59]	_
lto et al.	24	11	10	14	3	4	0.6%	10.00 [2.58, 17.42]	· · · · · · · · · · · · · · · · · · ·
Kang et al.	7.3	3	25	7.1	2.2	20	6.4%	0.20 [-1.32, 1.72]	+
Lai et al.	14.2	14	18	11.4	6.9	17	0.6%	2.80 [-4.45, 10.05]	
Lee et al.	5	0.3	131	5	0.75	37	11.4%	0.00 [-0.25, 0.25]	•
Liu et al.	8.58	3.6	102	7.67	2.19	102	9.4%	0.91 [0.09, 1.73]	-
Morelli et al.	8.8	3.8	15	6.5	1.9	15	4.5%	2.30 [0.15, 4.45]	
Raoof et al.	6	2.2	605	5	2.2	99	10.8%	1.00 [0.53, 1.47]	*
Souche et al.	9	3	23	8	2.25	15	5.9%	1.00 [-0.67, 2.67]	
Waters et al.	6	7.7	18	4	1	17	2.1%	2.00 [-1.59, 5.59]	+
Xourafas et al.	5	18.3	694	5	6	200	6.2%	0.00 [-1.60, 1.60]	+
Zhang et al.	14.4	7.2	31	12.8	6.8	43	2.5%	1.60 [-1.65, 4.85]	
Total (95% CI)			2584			879	100.0%	0.75 [0.17, 1.33]	
	75. 04:2	- 74 0		20 /0 ~ /	0000			0.70 [0.17, 1.00]	
Heterogeneity: Tau ² = 0 Test for overall effect: Z				20 (P < (1.0000	1); 1- = 7	370		-20 -10 0 10 20

Figure 2. Forest plots for length of hospital stay (LOS) between the groups.




Figure 3. Sensitivity analysis. As a result of the lack homogeneity between the studies, further analyses were performed.

2464

Endpoints

Overall, 21 studies provided extractable data from a total of 3463 patients concerning the primary endpoint (Figure 2). Meta-analysis of these data, showed a statistically significant (p=0.01) lower LOS (WMD: 0.75, 95%CI: 0.17-1.33) in the group where robotic distal pancreatectomies were performed. Heterogeneity levels were significantly high (Q test P<0.00001, I²=73%). As a result of the lack of homogeneity between the studies, further analyses were performed. Figure 3 (Supplementary Material), summarizes the results of the sensitivity analysis. Meta-regression regarding the year of publication (p=0.56), sample size (p=0.13), age (p=0.869), BMI (p=0.482), follow up (p=0.06) and tumor size (p=0.83) did not provide any statistically significant results. Furthermore, subgroup analysis was performed, in order to identify possibly heterogeneity introducing factors (Table 6 Supplementary Material). Heterogeneity was reduced without altering the outcome of the primary endpoints when studies applying a prospective design (WMD: 1.43, 95%CI: 0.19-2.73, Q test P=0.53, I²=0%), or a robotic assisted technique (WMD: 1, 95%CI: 0.58-1.43, Q test P=0.4, I²=4%), or stapling and over-sewing the pancreatic stump (WMD: 1.30, 95%CI: 0.42-2.19, Q test P=0.69, I²=0%) were introduced.

Table	5.	Newcastle-Ottawa	scoring
-------	----	------------------	---------

Study		Sele	ction		Comparability	Ex	posure/Outco	те	Total
-	1	2	3	4	5	6	7	8	
Fisher et al.	*	*	*	*		*	*	*	7/9
Raoof et al.	*	*	*	*		*	*	*	7/9
Souche et al.	*	*							2/9
Goh et al.	*	*	*			*		*	5/9
Ielpo et al.	*	*	*			*			4/9
Liu et al.	*	*			**	*	*		6/9
Xourafas et al.	*	*	*			*	*		5/9
Zhang et al.	*	*	*	*		*		*	6/9
Eckhardt et al.	*	*	*			*		*	5/9
Morelli et al.	*	*			**	*	*		6/9
Adam et al.	*	*	*		**	*	*		7/9
Butturini et al.	*	*	*			*		*	5/9
Chen et al.	*	*	*		**	*	*		7/9
Lai et al.	*	*	*			*	*		5/9
Lee et al.	*	*	*			*	*		5/9
Balzano et al.	*	*							2/9
Duran et al.	*	*	*			*			4/9
Ito et al.		*				*	*		3/9
Benizri et al.	*	*	*			*			4/9
Daouadi et al.	*	*	*			*			4/9
Kang et al.	*	*	*			*			4/9
Waters et al.	*	*	*			*			4/9

Table 6. Subgroup analysis results

Subgroup		WMD (95%CI)	Q test P	I^2
Prospective Study		1.46(0.19, 2.73)	0.53	0%
Multi Center		0.07(-1.40, 1.55)	0.04	68%
Robotic Assisted		1(0.58, 1.43)	0.4	4%
≥3 Surgeon		0.99(-0.27, 2.25)	0.004	71%
Experience in MDP		1.40(0.45, 2.35)	0.0001	77%
Pancreatic Stump	Stapler	0.99(-0.17, 2.15)	0.007	66%
	Stapler & Oversewn	1.30(0.42, 2.19)	0.69	0%

Regarding the other perioperative outcomes (Figure 4), although the operative duration was significantly higher in RDP (WMD: -28.29, 95%CI: -49.98--6.6, Q test P<0.00001, I²=87%), there was no significant difference in terms of intraoperative blood loss (WMD: 34, 95%CI: -10.28-78.29, Q test P<0.00001, I²=87%). In addition to this, the implementation of a robotic operative approach, resulted to significantly lower rates of open conversion (OR: 2.38, 95%CI: 1.75-3.22, Q test P<0.0001, I²=22%) and respectively, higher rates of spleen preservation (OR: 0.49, 95%CI: 0.31-0.79, Q test P=0.0005, I²=61%) (Figure 5). The percentages of perioperative blood transfusion did not differ between LDP and RDP (Figure 5, OR: 0.99, 95%CI: 0.66-1.49, Q test P=0.7, I²=0%).

RDP and LDP were equivalent in terms of overall postoperative morbidity (Figure 6, OR: 1.08, 95%CI: 0.88-1.32, Q test P=0.83, I²=0%). More specifically, no statistical difference was identified in the rates of POPF grade A (OR: 1.12, 95%CI:

0.79-1.59, Q test P=1, I²=0%), POPF grade B (OR: 1.04, 95%CI: 0.71-1.53, Q test P=0.54, I²=0%), POPF grade C (OR: 0.89, 95%CI: 0.38-2.09, Q test P=0.76, I²=0%), CD ≥III adverse events (OR: 0.92, 95%CI: 0.62-1.38, Q test P=0.18, I²=27%), fluid collections (OR: 1.37, 95%CI: 0.68-2.75, Q test P=0.49, I²=0%), postoperative hemorrhage (OR: 0.98, 95%CI: 0.58-1.68, Q test P=0.85, I²=0%), SSI (OR: 0.77, 95%CI: 0.43-1.38, Q test P=0.55, I²=0%), reoperation (OR: 1.34, 95%CI: 0.71-2.52, Q test P=0.74, I²=0%), readmission (OR: 0.73, 95%CI: 0.44-1.20, Q test P=0.49, I²=0%) and mortality (OR: 2.87, 95%CI: 0.67-12.38, Q test P=0.71, I²=0%) (Figure 7, Supplementary Material).

Positive resection margin risk did not differ between the two study subgroups (Figure 8A Supplementary Material, RD: 0.02, 95%CI: -0.02-0.07, Q test P=0.04, I²=48%). Despite this, a higher lymph node yield was achieved through the robotic approach (Figure 8B Supplementary Material, WMD: -2.09, 95%CI: -4.17--0.01, Q test P<0.00001, I²=86%).

Study or Subgroup		LDP			RDP			Mean Difference	Mean Difference
	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Desire stat	404	05	00	005	05		0.40/		
Benizri et al.	194	35	23	225	35	11	6.4%	-31.00 [-56.15, -5.85]	7
Butturini et al.	195	67.5	21	265	68.7	22	5.6%	-70.00 [-110.71, -29.29]	
Chen et al.	200	62.2	50	150	44.4	69	6.6%	50.00 [29.83, 70.17]	
Daouadi et al.	372	141	94	293	93	30	5.4%	79.00 [35.18, 122.82]	
Duran et al.	250	45.1	18	315	62.1	16	5.8%	-65.00 [-101.88, -28.12]	
Eckhardt et al.	195	77.5	29	229	42	12	5.8%	-34.00 [-70.88, 2.88]	
Goh et al.	245	86.2	31	452.5	96.2	8	3.9%	-207.50 [-280.74, -134.26]	
lelpo et al.	241	65	26	294	105	28	5.3%	-53.00 [-99.23, -6.77]	
lto et al.	292	153	10	306	29	4	2.8%	-14.00 [-113.00, 85.00]	
Kang et al.	258	118.6	25	348.7	121.8	20	4.0%	-90.70 [-161.49, -19.91]	
Lai et al.	173.6	45.6	18	221.4	73.2	17	5.6%	-47.80 [-88.48, -7.12]	
Lee et al.	193	45.3	131	213	55.7	37	6.6%	-20.00 [-39.55, -0.45]	
Liu et al.	199.56	66.82	102	207.06	65.45	102	6.6%	-7.50 [-25.65, 10.65]	+
Morelli et al.	279	48	15	220	73	15	5.4%	59.00 [14.79, 103.21]	——
Souche et al.	187	51.25	23	207	40	15	6.2%	-20.00 [-49.13, 9.13]	+
Waters et al.	224	61.5	18	298	56.7	17	5.7%	-74.00 [-113.16, -34.84]	
Xourafas et al.	205	138.75	694	243	249.5	200	5.8%	-38.00 [-74.09, -1.91]	
Zhang et al. Subtotal (95% CI)	133.4	41.8	31 1359	139.3	56.9	43 666	6.5% 100.0%	-5.90 [-28.39, 16.59] -28.29 [-49.98, -6.60]	
Heterogeneity: Tau ² = 1 Test for overall effect: Z			57, ai =	17 (P < 0	.00001),	1 - 07 /	0		
Test for overall effect: Z	= 2.56 (P	= 0.01)		·	,.				
Test for overall effect: Z Benizri et al.	= 2.56 (P 345	= 0.01) 332.4	23	515	377.2	11	2.3%	-170.00 [-431.04, 91.04]	·
Test for overall effect: Z Benizri et al. Chen et al.	= 2.56 (P 345 290	= 0.01) 332.4 170	23 50	515 100	377.2 111.1	11 69	2.3% 9.8%	190.00 [136.08, 243.92]	·
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al.	= 2.56 (P 345 290 150	= 0.01) 332.4 170 148	23 50 94	515 100 150	377.2 111.1 148	11 69 30	2.3% 9.8% 9.4%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83]	·
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al.	= 2.56 (P 345 290 150 100	= 0.01) 332.4 170 148 197.5	23 50 94 29	515 100 150 100	377.2 111.1 148 17.5	11 69 30 12	2.3% 9.8% 9.4% 8.8%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56]	·
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al.	= 2.56 (P 345 290 150 100 100	= 0.01) 332.4 170 148 197.5 337.5	23 50 94 29 31	515 100 150 100 350	377.2 111.1 148 17.5 212.5	11 69 30 12 8	2.3% 9.8% 9.4% 8.8% 3.7%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80]	
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al. lelpo et al.	= 2.56 (P 345 290 150 100 100 181	= 0.01) 332.4 170 148 197.5 337.5 137.5	23 50 94 29 31 26	515 100 150 100 350 175	377.2 111.1 148 17.5 212.5 65	11 69 30 12 8 28	2.3% 9.8% 9.4% 8.8% 3.7% 9.6%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80] 6.00 [-52.08, 64.08]	·
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al.	= 2.56 (P 345 290 150 100 100	= 0.01) 332.4 170 148 197.5 337.5	23 50 94 29 31 26 10	515 100 150 100 350	377.2 111.1 148 17.5 212.5	11 69 30 12 8	2.3% 9.8% 9.4% 8.8% 3.7%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80]	·
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al. lelpo et al.	= 2.56 (P 345 290 150 100 100 181	= 0.01) 332.4 170 148 197.5 337.5 137.5	23 50 94 29 31 26	515 100 150 100 350 175 61.7	377.2 111.1 148 17.5 212.5 65	11 69 30 12 8 28	2.3% 9.8% 9.4% 8.8% 3.7% 9.6% 8.2% 2.8%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80] 6.00 [-52.08, 64.08]	
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al. leipo et al. Ito et al.	= 2.56 (P 345 290 150 100 100 181 153	= 0.01) 332.4 170 148 197.5 337.5 137.5 71	23 50 94 29 31 26 10	515 100 150 100 350 175 61.7	377.2 111.1 148 17.5 212.5 65 72	11 69 30 12 8 28 4	2.3% 9.8% 9.4% 8.8% 3.7% 9.6% 8.2%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80] 6.00 [-52.08, 64.08] 91.30 [8.14, 174.46]	
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al. lelpo et al. Ito et al. Kang et al.	= 2.56 (P 345 290 150 100 100 181 153 420.2	= 0.01) 332.4 170 148 197.5 337.5 137.5 71 445.5	23 50 94 29 31 26 10 25	515 100 150 100 350 175 61.7 372	377.2 111.1 148 17.5 212.5 65 72 341.5	11 69 30 12 8 28 4 20	2.3% 9.8% 9.4% 8.8% 3.7% 9.6% 8.2% 2.8%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80] 6.00 [-52.08, 64.08] 91.30 [8.14, 174.46] 48.20 [-181.79, 278.19]	
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al. Ielpo et al. Ito et al. Kang et al. Lai et al.	= 2.56 (P 345 290 150 100 100 181 153 420.2 268.3	= 0.01) 332.4 170 148 197.5 337.5 137.5 71 445.5 645	23 50 94 29 31 26 10 25 18	515 100 150 100 350 175 61.7 372 100.3	377.2 111.1 148 17.5 212.5 65 72 341.5 72.5	11 69 30 12 8 28 4 20 17	2.3% 9.8% 9.4% 8.8% 3.7% 9.6% 8.2% 2.8% 1.8%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80] 6.00 [-52.08, 64.08] 91.30 [8.14, 174.46] 48.20 [-181.79, 278.19] 168.00 [-131.96, 467.96]	
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al. Ielpo et al. Ito et al. Kang et al. Lai et al. Liu et al.	= 2.56 (P 345 290 150 100 100 181 153 420.2 268.3 100	= 0.01) 332.4 170 148 197.5 337.5 137.5 71 445.5 645 111.1	23 50 94 29 31 26 10 25 18 102	515 100 150 100 350 175 61.7 372 100.3 100	377.2 111.1 148 17.5 212.5 65 72 341.5 72.5 111.1	11 69 30 12 8 28 4 20 17 102	2.3% 9.8% 9.4% 8.8% 3.7% 9.6% 8.2% 2.8% 1.8%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80] 6.00 [-52.08, 64.08] 91.30 [8.14, 174.46] 48.20 [-181.79, 278.19] 168.00 [-131.96, 467.96] 0.00 [-30.49, 30.49]	
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al. Ito et al. Kang et al. Lai et al. Liu et al. Morelli et al.	= 2.56 (P 345 290 150 100 100 181 153 420.2 268.3 100 200	= 0.01) 332.4 170 148 197.5 337.5 137.5 71 445.5 645 111.1 28	23 50 94 29 31 26 10 25 18 102 15	515 100 150 100 350 175 61.7 372 100.3 100 189	377.2 111.1 148 17.5 212.5 65 72 341.5 72.5 111.1 17	11 69 30 12 8 28 4 20 17 102 15	2.3% 9.8% 9.4% 8.8% 3.7% 9.6% 8.2% 2.8% 1.8% 10.9% 11.3%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80] 91.30 [8.14, 174.46] 48.20 [-181.79, 278.19] 168.00 [-131.96, 467.96] 0.00 [-30.49, 30.49] 11.00 [-5.58, 27.58]	
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al. Ieipo et al. Ito et al. Kang et al. Lai et al. Liu et al. Morelli et al. Souche et al.	= 2.56 (P 345 290 150 100 100 181 153 420.2 268.3 100 200 110	= 0.01) 332.4 170 148 197.5 337.5 137.5 71 445.5 645 111.1 28 85	23 50 94 29 31 26 10 25 18 102 15 23	515 100 150 100 350 175 61.7 372 100.3 100 189 130	377.2 111.1 148 17.5 212.5 65 72 341.5 72.5 111.1 17 30	11 69 30 12 8 28 4 20 17 102 15 15	2.3% 9.8% 9.4% 8.8% 3.7% 9.6% 8.2% 2.8% 1.8% 10.9% 11.3%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80] 91.30 [8.14, 174.46] 48.20 [-181.79, 278.19] 168.00 [-131.96, 467.96] 0.00 [-30.49, 30.49] 11.00 [-5.58, 27.58] -20.00 [-57.91, 17.91]	
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al. leipo et al. Ito et al. Kang et al. Lai et al. Liu et al. Morelli et al. Souche et al. Waters et al.	= 2.56 (P 345 290 150 100 100 181 153 420.2 268.3 100 200 110 667	= 0.01) 332.4 170 148 197.5 337.5 137.5 71 445.5 645 111.1 28 85 1,737	23 50 94 29 31 26 10 25 18 102 15 23 18	515 100 150 100 350 175 61.7 372 100.3 100 189 130 279	377.2 111.1 148 17.5 212.5 65 72 341.5 72.5 111.1 17 30 295	11 69 30 12 8 28 4 20 17 102 15 15 17	2.3% 9.8% 9.4% 8.8% 3.7% 9.6% 8.2% 2.8% 1.8% 10.9% 11.3% 10.6% 0.3%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80] 91.30 [8.14, 174.46] 48.20 [-181.79, 278.19] 168.00 [-131.96, 467.96] 0.00 [-30.49, 30.49] 11.00 [-5.58, 27.58] -20.00 [-5.79, 17.91] 388.00 [-426.60, 1202.60]	
Test for overall effect: Z Benizri et al. Chen et al. Daouadi et al. Eckhardt et al. Goh et al. Ico et al. Ito et al. Liu et al. Liu et al. Liu et al. Souche et al. Waters et al. Zhang et al.	= 2.56 (P 345 290 150 100 100 181 153 420.2 268.3 100 200 110 667 200	= 0.01) 332.4 170 148 137.5 337.5 137.5 71 445.5 645 111.1 28 85 1,737 103.7	23 50 94 29 31 26 10 25 18 102 15 23 18 31 495	515 100 150 350 175 61.7 372 100.3 100 189 130 279 50	377.2 111.1 148 17.5 212.5 65 72 341.5 72.5 111.1 17 30 295 37.3	11 69 30 12 8 28 4 20 17 102 15 15 15 17 43 391	2.3% 9.8% 9.4% 8.8% 3.7% 9.6% 2.8% 1.8% 10.9% 11.3% 10.6% 0.3% 10.6% 10.0%	190.00 [136.08, 243.92] 0.00 [-60.83, 60.83] 0.00 [-72.56, 72.56] -250.00 [-439.20, -60.80] 6.00 [-52.08, 64.08] 91.30 [8.14, 174.46] 48.20 [-181.79, 278.19] 168.00 [-30.49, 30.49] 11.00 [-55.81, 75.8] -20.00 [-57.91, 17.91] 388.00 [-426.60, 1202.60] 150.00 [111.83, 188.17]	

Figure 4. Perioperative outcomes. Forest plots of perioperative outcomes for (A) operative duration and (B) intraoperative blood loss.

۸		LDF	,	RDF	,		Odds Ratio		Odd	s Ratio		
А	Study or Subgroup	Events			Total	Weight	M-H, Fixed, 95% CI			ed, 95% Cl		
	Balzano et al.	29	140	0	31	1.0%	16.67 [0.99, 280.49]					\rightarrow
	Benizri et al.	5	23	2	11	3.3%	1.25 [0.20, 7.75]			+	-	
	Butturini et al.	1	21	1	22	1.5%	1.05 [0.06, 17.95]			+		
	Chen et al.	3	50	0	69		10.24 [0.52, 202.87]		-			\rightarrow
	Daouadi et al.	15	94	0	30	1.0%	11.89 [0.69, 204.98]			-		\rightarrow
	Duran et al.	5	18	2	16	2.4%	2.69 [0.44, 16.37]		_			
	Eckhardt et al. Goh et al.	1 10	29 31	1	12 8	2.1% 0.8%	0.39 [0.02, 6.85]	_				
	Gon et al. lelpo et al.	10	31 26	1	28	0.8%	8.30 [0.44, 158.00] 6.43 [0.70, 59.28]		_			_
	lto et al.	5	20	0	20	0.9%	1.42 [0.05, 42.22]					_
	Lee et al.	41	131	14	37	23.4%	0.75 [0.35, 1.60]		_	+		
	Liu et al.	10	102	3	102	4.2%	3.59 [0.96, 13.44]				_	
	Morelli et al.	1	15	0	15	0.7%	3.21 [0.12, 85.20]					
	Raoof et al.	165	605	10	99	19.5%	3.34 [1.69, 6.57]				•	
	Souche et al.	0	23	0	15		Not estimable					
	Waters et al.	2	18	2	17	2.9%	0.94 [0.12, 7.52]				-	
	Xourafas et al.	112	694	17	200	34.5%	2.07 [1.21, 3.54]			_		
	Zhang et al.	0	31	0	43		Not estimable					
	Total (95% CI)		2061		759	100.0%	2.38 [1.75, 3.22]			•		
	Total events	406		53								
	Heterogeneity: Chi ² = 1				22%			0.01	0.1	+	10	100
	Test for overall effect: Z	: = 5.56 (P	< 0.000	001)								
_		LDF		RD			Odda Datia		<u></u>	ls Ratio		
B	Okudu az Oubazaun					Waiaht	Odds Ratio					
υ.	Study or Subgroup	Events		Events	Total	Weight			M-H, FIX	ed, 95% Cl		
	Benizri et al.	3	23	2	11	5.1%						
	Butturini et al.	0	21	3	22	7.2%		-				_
	Chen et al.	7	50	2	69	3.1%						•
	Daouadi et al.	12	94	3	30	8.6%				T		
	Duran et al.	0	18	1	16	3.3%					-	
	Eckhardt et al.	3	29	2	12	5.5%						
	Goh et al.	4	31	1	8	3.0%					_	
	Kang et al.	4	25	4	20	8.1%						
	Liu et al.	4	102	3	102	6.2%				<u>+</u>		
	Morelli et al.	1	15	1	15	2.0%						
	Souche et al.	0	23	0	15		Not estimable					
	Xourafas et al.	37	694	13	200	41.4%				•		
	Zhang et al.	4	31	4	43	6.3%	1.44 [0.33, 6.28]			T		
	Total (95% CI)		1156		563	100.0%	0.99 [0.66, 1.49]			▲		
	Total events	79	1100	39	500	100.070	0.33 [0.00, 1.43]			T		
	Heterogeneity: Chi ² = 8		1 (P = (n%			<u> </u>	_	—	-	_
	Test for overall effect: 2				0 /0			0.01	0.1	1	10	100
		(-		,								
C		LDP		RDP			Odds Ratio		Od	ds Ratio		
C	Study or Subgroup		Total		Total	Weight	M-H, Random, 95% CI			dom, 95% Cl		
	Balzano et al.	89	140	27	31	6.7%	0.26 [0.09, 0.78]			-T		
	Benizri et al.	12	23	5	11	5.3%	1.31 [0.31, 5.53]			+		
	Butturini et al.	4	21	6	22	5.4%	0.63 [0.15, 2.64]			+		
	Chen et al.	13	50	45	69	8.2%	0.19 [0.08, 0.42]		_			
	Daouadi et al. Duran et al.	17 2	94 18	2 4	30 16	5.0% 4.0%	3.09 [0.67, 14.24]					
	Eckhardt et al.	23	29	4	10	4.0%	0.38 [0.06, 2.40] 0.35 [0.04, 3.26]					
	Goh et al.	6	31	5	8	4.5%	0.14 [0.03, 0.78]	-		-1		
	lelpo et al.	23	26	23	28	5.0%	1.67 [0.36, 7.80]		_	-	_	
	Kang et al.	16	25	19	20	3.3%	0.09 [0.01, 0.82]			-1		
	Lai et al.	7	18	9	17	5.7%	0.57 [0.15, 2.17]			+-		
	Lee et al.	29	131	3	37	6.1%	3.22 [0.92, 11.25]			+	_	
	Liu et al.	50	102	62	102	9.4%	0.62 [0.36, 1.08]			1		
	Morelli et al.	11	15	15	15	2.0%	0.08 [0.00, 1.69]	+				
	Souche et al. Waters et al	12	23 18	13 11	15 17	4.5% 5.4%	0.17 [0.03, 0.92]					
	Waters et al. Xourafas et al.	5 60	18 694	11 16	17 200	5.4% 9.3%	0.21 [0.05, 0.88] 1.09 [0.61, 1.93]			_		
	Zhang et al.	15	094 31	34	200 43	9.3% 7.2%	0.25 [0.09, 0.69]			-1		
	-			•								
	Total (95% CI)		1489		693	100.0%	0.49 [0.31, 0.79]		•	▶		
	Total events Heterogeneity: Tau ² = 0	394 53: Chi² =	43.07	310 df = 17 (P	= 0.000)5)· 2 = 61	~	—				
	Test for overall effect: Z				0.000			0.01	0.1	1	10	100
				-								

Figure 5. Open conversion, blood transfusion and spleen preservation. Forest plots of open conversion **(A)**, blood transfusion **(B)** and spleen preservation **(C)**.

	LDP		RDI	>		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Benizri et al.	11	23	6	11	2.4%	0.76 [0.18, 3.23]	
Butturini et al.	15	21	15	22	2.4%	1.17 [0.32, 4.30]	
Chen et al.	24	50	28	69	6.9%	1.35 [0.65, 2.82]	_ _
Daouadi et al.	60	94	20	30	6.2%	0.88 [0.37, 2.10]	
Eckhardt et al.	17	29	7	12	2.3%	1.01 [0.26, 3.96]	
Goh et al.	20	31	7	8	2.2%	0.26 [0.03, 2.39]	
lelpo et al.	6	26	6	28	2.5%	1.10 [0.30, 3.97]	
lto et al.	2	10	1	4	0.6%	0.75 [0.05, 11.65]	
Kang et al.	4	25	2	20	1.1%	1.71 [0.28, 10.48]	
Lai et al.	7	18	8	17	2.8%	0.72 [0.19, 2.74]	
Lee et al.	70	131	22	37	9.1%	0.78 [0.37, 1.64]	
Liu et al.	45	102	41	102	13.0%	1.17 [0.67, 2.05]	- -
Morelli et al.	8	15	3	15	0.8%	4.57 [0.90, 23.14]	
Souche et al.	11	23	5	15	1.8%	1.83 [0.48, 7.07]	
Waters et al.	6	18	3	17	1.2%	2.33 [0.48, 11.40]	
Xourafas et al.	250	694	74	200	41.6%	0.96 [0.69, 1.33]	+
Zhang et al.	13	31	11	43	3.0%	2.10 [0.78, 5.65]	+
Subtotal (95% CI)		1341		650	100.0%	1.08 [0.88, 1.32]	•
Total events	569		259				
Heterogeneity: Chi ² = 1	0.68, df =	16 (P =	0.83); l ² =	:0%			
Test for overall effect: 2	Z = 0.71 (P	= 0.48)					
							0.01 0.1 1 10 1

Figure 6. Overall morbidity. Forest plots on the comparison of overall morbidity

	0	LDP	T 1	RDP		Mr	Odds Ratio	Odds Ratio				
	Study or Subgroup		Total		Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl				
А	Benizri et al. Butturini et al.	5 8	23 21	2 8	11 22	3.6% 8.2%	1.25 [0.20, 7.75] 1.08 [0.31, 3.71]					
	Chen et al. Daouadi et al.	6 23	50 94	5 6	69 30	6.3% 11.6%	1.75 [0.50, 6.08] 1.30 [0.47, 3.56]					
	Duran et al. Eckhardt et al.	0	18 29	2 3	16 12	4.4% 5.2%	0.16 [0.01, 3.53] 1.14 [0.25, 5.33]	·				
	Goh et al. lelpo et al.	11 2	31 26	3	8	5.2% 3.0%	0.92 [0.18, 4.58] 1.08 [0.14, 8.31]					
	Lai et al. Lee et al.	1	18	1	17	1.6%	0.94 [0.05, 16.35]	- <u></u>				
	Liu et al.	3 23	131 102	24	102	2.6% 31.5%	0.84 [0.09, 8.36] 0.95 [0.49, 1.82]					
	Morelli et al. Souche et al.	4 8	15 23	2 5	15 15	2.5% 6.7%	2.36 [0.36, 15.45] 1.07 [0.27, 4.22]					
	Zhang et al. Subtotal (95% CI)	7	31 612	7	43 425	7.7% 100.0%	1.50 [0.47, 4.82] 1.12 [0.79, 1.59]	+				
	Total events Heterogeneity: Chi ² = 3	109 1.36. df = 13	8 (P = 1	71 .00): I ² = 0	%							
_	Test for overall effect: 2	Z = 0.63 (P	= 0.53)									
В	Benizri et al. Butturini et al.	2 4	23 21	3	11 22	7.4% 3.2%	0.25 [0.04, 1.81] 2.35 [0.38, 14.47]					
	Chen et al. Daouadi et al.	10 11	50 94	12 4	69 30	16.1% 10.7%	1.19 [0.47, 3.01] 0.86 [0.25, 2.94]					
	Duran et al. Eckhardt et al.	2	18 29	8 3	16 12	15.0% 7.0%	0.13 [0.02, 0.73] 0.63 [0.12, 3.17]					
	Goh et al. lelpo et al.	7	31 26	2	8 28	4.9% 1.8%	0.88 [0.14, 5.34] 2.25 [0.19, 26.41]					
	Lai et al. Lee et al.	5	18 131	5	17 37	7.4% 5.8%	0.92 [0.21, 4.00] 1.14 [0.23, 5.61]					
	Liu et al.	12	102	7	102	12.3%	1.81 [0.68, 4.80]					
	Morelli et al. Souche et al.	3	15 23	0	15 15	1.6% 1.1%	3.50 [0.32, 38.23] 2.07 [0.08, 54.12]					
	Zhang et al. Subtotal (95% CI)	4	31 612	4	43 425	5.8% 100.0%	1.44 [0.33, 6.28] 1.04 [0.71, 1.53]	+				
	Total events Heterogeneity: Chi ² = 1	76 1.86, df = 1	13 (P =	54 0.54); I ² =	0%							
-	Test for overall effect: 2	Z = 0.20 (P				5 70/	4 50 10 00 40 001					
C	Benizri et al. Butturini et al.	1	23 21	0	11 22	5.7% 13.0%	1.53 [0.06, 40.69] 0.33 [0.01, 8.65]					
	Chen et al. Daouadi et al.	0	50 94	0	69 30	52.3%	Not estimable 0.37 [0.09, 1.46]					
	Eckhardt et al. Goh et al.	1 0	29 31	0	12 8	6.0%	1.32 [0.05, 34.58] Not estimable					
	lelpo et al. Lai et al.	0	26 18	0	28 17	4.3%	Not estimable 3.00 [0.11, 78.81]					
	Liu et al. Morelli et al.	1	102 15	0	102 15	4.5%	3.03 [0.12, 75.25] Not estimable					
	Souche et al. Zhang et al.	1	23 31	1	15	10.5% 3.7%	0.64 [0.04, 11.02] 4.28 [0.17, 108.59]					
	Subtotal (95% CI) Total events	11	463	6	372	100.0%	0.89 [0.38, 2.09]	-				
	Heterogeneity: Chi ² = 4 Test for overall effect: 2	.15, df = 7	(P = 0.7	76); I ² = 09	6							
D	Test for overall effect: 2 Benizri et al.	z = 0.27 (P 4	= 0.79) 23	3	11	6.7%	0.56 [0.10, 3.10]					
J	Butturini et al. Chen et al.	1	21 50	3	22 69	5.5% 9.0%	0.32 [0.03, 3.32] 1.17 [0.34, 4.06]					
	Daouadi et al. Duran et al.	13 8	94 18	6	30 16	15.6% 0.6%	0.64 [0.22, 1.87] 26.71 [1.39, 513.09]					
	Eckhardt et al. leipo et al.	9	29 26	4 2	12 28	7.7%	0.90 [0.21, 3.78] 2.36 [0.39, 14.15]					
	Lee et al.	29	131 102	16	37 102	38.6%	0.37 [0.17, 0.81]	_ _				
	Liu et al. Morelli et al.	6	15	5	15	9.3% 0.9%	1.21 [0.36, 4.11] 3.21 [0.12, 85.20]					
	Souche et al. Zhang et al.	3 1	23 31	1	15 43	2.1% 0.8%	2.10 [0.20, 22.33] 4.28 [0.17, 108.59]					
	Subtotal (95% CI) Total events	84	563	46	400	100.0%	0.92 [0.62, 1.38]	T				
	Heterogeneity: Chi ² = 1 Test for overall effect: 2	5.14, df = 1 Z = 0.39 (P	11 (P = = 0.70)	0.18); I ^z =	27%							
Е	Butturini et al. Eckhardt et al.	3 6	21 29	7	22 12	41.9% 16.0%	0.36 [0.08, 1.63] 1.30 [0.22, 7.61]	_				
	Lai et al. Lee et al.	3 14	18 131	1 2	17	6.1% 19.9%	3.20 [0.30, 34.24]					
	Morelli et al.	1	15	0	15	3.2%	2.09 [0.45, 9.66] 3.21 [0.12, 85.20]					
	Souche et al. Subtotal (95% CI)	6	23 237	2	15 118	12.8% 100.0%	2.29 [0.40, 13.28] 1.37 [0.68, 2.75]					
	Total events 33 14 Heterogeneity: Chi ² = 4.40, df = 5 (P = 0.49); i ² = 0%											
F	Test for overall effect: 2 Benizri et al.	2 = 0.88 (P 1	= 0.38) 23	1	11	4.6%	0.45 [0.03, 8.02]					
	Butturini et al. Eckhardt et al.	2	21 29	1	22 12	3.2% 9.1%	2.21 [0.19, 26.38] 0.58 [0.08, 3.98]					
	Laietal. Lee etal.	0	18 131	1	17 37	5.4% 2.7%	0.30 [0.01, 7.81] 3.26 [0.18, 60.33]					
	Liu et al. Waters et al.	2	102	1	102 17	3.5% 1.7%	2.02 [0.18, 22.63] 3.00 [0.11, 78.81]					
	Xourafas et al.	37	694	13	200	68.4%	0.81 [0.42, 1.56]					
	Zhang et al. Subtotal (95% CI) Total events	1	31 1067	0	43 461	1.4% 100.0%	4.28 [0.17, 108.59] 0.98 [0.58, 1.66]	•				
	Heterogeneity: Chi ² = 4	52 .07, df = 8	(P = 0.8	19 35); I² = 0%	6							
c	Test for overall effect: 2 Eckhardt et al.	2 = 0.06 (P 0	= 0.95) 29	0	12		Not estimable					
G	Lai et al. Xourafas et al.	1 40	18 694	1 16	17 200	3.9% 94.5%	0.94 [0.05, 16.35] 0.70 [0.39, 1.28]					
	Zhang et al. Subtotal (95% CI)	1	31 772	0	43 272	1.6% 100.0%	4.28 [0.17, 108.59] 0.77 [0.43, 1.38]					
	Total events Heterogeneity: Chi ² = 1	42 .19. df = 2		17 55): l² = 0%				-				
	Test for overall effect: 2	Z = 0.88 (P	= 0.38)									
Н	Benizri et al. Butturini et al.	2 1	23 21	1 3	11 22	7.1% 16.0%	0.95 [0.08, 11.79] 0.32 [0.03, 3.32]					
	Chen et al. Duran et al.	2 0	50 18	0	69 16	2.3%	7.16 [0.34, 152.57] Not estimable	` ,				
	Eckhardt et al. Ielpo et al.	3	29 26	2	12 28	14.5% 2.5%	0.58 [0.08, 3.98] 5.82 [0.27, 127.06]	,				
	Liu et al. Souche et al.	2	102 23	1	102 15	5.6% 6.6%	2.02 [0.18, 22.63]					
	Xourafas et al. Zhang et al.	23	694 31	5	200 43	43.0% 2.3%	1.34 [0.50, 3.56]					
	Subtotal (95% CI) Total events	37	1017	13	518	100.0%	4.28 [0.17, 108.59] 1.34 [0.71, 2.52]	· · · · · · · · · · · · · · · · · · ·				
	Heterogeneity: Chi ² = 5	5.14, df = 8	(P = 0.7 = 0.36)	74); I² = 0%	6							
1	Test for overall effect: 2 Butturini et al.	1	21	4	22	11.3%	0.23 [0.02, 2.20]					
1	Daouadi et al. Goh et al.	22 6	94 31	11 2	30 8	38.6% 7.8%	0.53 [0.22, 1.28] 0.72 [0.12, 4.50]					
	Liu et al. Morelli et al.	0	102 15	0	102 15		Not estimable Not estimable					
	Raoof et al. Subtotal (95% CI)	57	605 868	9	99 276	42.4% 100.0%	1.04 [0.50, 2.17] 0.73 [0.44, 1.20]					
	Total events Heterogeneity: Chi ² = 2	86 .43. df = 3		26 19); l² = 0%				-				
	Test for overall effect: 2	Z = 1.24 (P	= 0.21)									
J	Butturini et al. Chen et al.	0	21 50	0	22 69		Not estimable Not estimable					
	Daouadi et al. Duran et al.	1	94 18	0 0	30 16	23.8%	0.98 [0.04, 24.65] Not estimable					
	Eckhardt et al.	0	29	0	12		Not estimable Not estimable					
	Kang et al. Lai et al.	0	18	0	17		Not estimable					
	Lee et al. Morelli et al.	0	131 15	0	37 15	oo	Not estimable Not estimable					
	Raoof et al. Souche et al.	16 0	605 23	0	99 15	26.8%	5.57 [0.33, 93.59] Not estimable					
	Waters et al. Xourafas et al.	0 8	18 694	0 1	17 200	49.3%	Not estimable 2.32 [0.29, 18.67]	_				
	Zhang et al. Subtotal (95% CI)	0	31 1772	0	43 612	100.0%	Not estimable 2.87 [0.67, 12.38]					
	Total events Heterogeneity: Chi ² = 0	25 0.68, df = 2	(P = 0.7	1 (1); I² = 09	6							
	Test for overall effect: 2	2 = 1.42 (P	= 0.16)	. 1				0.01 0.1 1 10 100				

Figure 7. Postoperative complications. Forest plots on the comparisons of postoperative complications showing the results for **A** postoperative pancreatic fistula (POPF), ISGF classification A, **B** POPF ISGPF classification B, **C** POPF ISGPF classification C, **D** Clavien-Dindo \geq 3, Complication, **E** Fluid collection, **F** Postoperative hemorrhage, **G** Surgical site infection (SSI), **H** Reoperation, **I** Readmission, and **J** mortality.

		Experimental Control						Risk	Difference	Risk Difference				
Α	Study or Subgroup	y or Subgroup Events Total Events Tota		Total	Weight	M-H, R	andom, 95% Cl	M-ł	M-H, Random, 95% Cl					
	Butturini et al.	()	21	0	22	12.9%	6 O.	00 [-0.09, 0.09]		+			
	Chen et al.	,		10	0	15	3.79		10 [-0.12, 0.32]			-		
	Daouadi et al.	60		94	9	30	4.6%		0.34 [0.15, 0.53]		<u> </u>			
	Duran et al.	()	18	0	16	10.2%		00 [-0.11, 0.11]		-			
	lelpo et al.	()	26	0	28	15.3%		00 [-0.07, 0.07]		+			
	Lee et al.	(19	0	4	2.59		00 [-0.27, 0.27]		—			
	Racof et al.	93		305	16	99	14.0%		01 [-0.09, 0.07]		-			
	Souche et al.	,		23	0	15	8.29		04 [-0.09, 0.17]		_ _			
	Waters et al.	(18	0	17	10.6%		00 [-0.10, 0.10]		-			
	Zhang et al.	(31	0	43	17.9%		00 [-0.05, 0.05]		+			
	Linding of di.		,	01	v	-10	11.07		00 ['0.00, 0.00]					
	Total (95% CI)		8	365		289	100.0%	0.	02 [-0.02, 0.07]		•			
	Total events	otal events 155 25												
	Heterogeneity: Tau ² = 0	Heterogeneity: Tau ² = 0.00; Chi ² = 17.46, df = 9 (P = 0.04)					2 = 48%		⊢ -1	-0.5	0	0.5		
	Test for overall effect: 2	est for overall effect: Z = 0.93 (P = 0.35)							-1	-0.0	v	0.0	1	
		DD			חחח		Mean Difference		Maan Differen					
D	Study or Subgroup	LDP RDP ly or Subgroup Mean SD Total Mean SD			Total	Weight	IV, Random, 95% (2	Mean Difference IV, Random, 95% Cl					
D	Adam et al.	12	9	474	12	10	61	10.9%	0.00 [-2.64, 2.64]		rv, nanuolii, 33/			
	Butturini et al.		9 11.5	21	11.5	9.25	22	6.0%	3.50 [-2.76, 9.76]					
	Chen et al.	15.2	3.3	10	15.5	3.1	15	11.0%	-0.30 [-2.88, 2.28]		_			
	Daouadi et al.	9	2.9	14	19	5.1	13		-10.00 [-13.16, -6.84]		-			
	Duran et al.	5	2	18	12.5	7.7	16	9.1%	-7.50 [-11.38, -3.62]					
	lelpo et al.	9.6	3.5	26	14.2	4	28	11.8%	-4.60 [-6.60, -2.60]					
	Lee et al.	10.4	8	19	12	7.2	4	4.5%	-1.60 [-9.52, 6.32]	-				
	Raoof et al.	12	8.8	605	11	11.1	99	11.4%	1.00 [-1.30, 3.30]					
	Souche et al.	7	2.75	23	6	2.5	15	12.2%	1.00 [-0.69, 2.69]		<u>+</u> -			
	Zhang et al.	2	0.74	31	3.5	3.5	43	12.8%	-1.50 [-2.58, -0.42]					
	Total (95% CI)	al (95% CI) 1241 316							-2.09 [-4.17, -0.01]					
	, ,	Fotal (95% Cl) 1241 316 10 Heterogeneity: Tau ² = 8.47; Chi ² = 63.58, df = 9 (P < 0.00001); l ² = 86%								+	_ _	+ +		
	Test for overall effect: Z				0 (1 - 0		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			-10	-5 Ö	5 10		
			LDP			RDP			Mean Difference		Mean Differenc	e		
	Study or Subgroup	Mean		Total	Mean		Total	Weight	IV, Fixed, 95% Cl		IV, Fixed, 95% (
C	Chen et al.	8.9	3.1	50	9.1	3.4	69	18.2%	-0.20 [-1.38, 0.98]					
C	Goh et al.	7	2.3	31	7.7	2.3	8	7.8%	-0.70 [-2.49, 1.09]		ł			
	Kang et al.	8.5	3.8	25	7.9	2.8	20	6.7%	0.60 [-1.33, 2.53]		ł			
	Waters et al.	g		18			17	3.6%	0.00 [-2.65, 2.65]		1			
	Zhang et al.	6.4	1.4	31	6.2	1.3	43	63.7%	0.20 [-0.43, 0.83]		- F			
	Total (95% CI)	tal (95% CI) 155 157 100.0%							0.08 [-0.42, 0.58]					
	Heterogeneity: Chi ² = 1.37, df = 4 (P = 0.85); l ² = 0%									-100 -50	0	50	100	
	Test for overall effect: Z = 0.30 (P = 0.76)										U	50	100	

Figure 8. Oncologic outcomes. Forest plots on the comparisons of oncologic outcomes showing the results for **A** Positive resection margins, **B** Extracted lymph nodes and **C** Specimens length.




Figure 9. Cost analysis. Forest plots on cost analysis showing the results for the comparisons of **A** Operative cost, **B** Total hospitalization cost.




Figure 10. Funnel plot for the primary endpoint assessing the publication bias for the primary endpoint of the study (LOS).

RDP and LDP resulted to an equivalent specimen length (Figure 8C Supplementary Material, WMD: 0.08, 95%CI: -0.42-0.58, Q test P=0.85, I²=0%).

Finally, as far as the cost outcomes were concerned, statistically significant results were estimated in both analyses. More specifically, RDP was associated with higher operative (Figure 9A Supplementary Material, WMD: -2733.42, 95%CI: -4189.77--1277.08, Q test P<0.00001, I²=99%) and total costs (Figure 9B Supplementary Material, WMD: -3799.68, 95%CI: -4438.39--3160.98, Q test P=0.85, I²=0%), when compared to LDP.

Risk of bias across studies

The funnel plot of the primary endpoint is displayed in Figure 10 (Supplementary Material). Visual inspection of the graphical representation reveals an asymmetrical distribution of the eligible studies in the two sides of the combined effect size line. Furthermore, Egger's test was statistically significant, thus confirming the presence of publication bias (p=0.029).

Discussion

This systematic review and meta-analysis evaluated the safety and feasibility of RDP utilization in the treatment of benign and malignant disorders of the pancreas. The results show that RDP leads to decreased LOS, decreased rate of open conversion and increased spleen preservation rates, although

it seems to be costlier than LDP. Finally, RDP appears to be comparable, if not better, to LDP when oncological parameters, such as positive resection margins and number of lymph nodes harvested, are taken into consideration.

Operative duration is a major factor in robotic surgery, because the procedures tend to be more time consuming than the laparoscopic ones [43,44]. Individual studies that were published in the past comparing LDP with RDP in regards to this subject were not conclusive. Some authors [21] have reported statistically significant longer operation times for the RDP groups but others [38] did not observe such a difference. The two latest metaanalyses investigating the subject, concluded that LDP and RDP are equally long [13,45].

On the contrary, the results of the present meta-analysis suggest that a difference in the duration of these procedures does exist, with the operative duration being longer in the RDP group. This dissonance between the results of this and past metaanalyses may be explained by the larger number of studies included in the current article offering a more comprehensive picture of the subject.

Spleen preserving distal pancreatectomy is the operation of choice in benign diseases of the pancreatic body and tail [46-48], as it possesses the benefits of lower risk of developing cancer in the future and prevents overwhelming post-splenectomy infection [49]. Spleen preservation is feasible both with LDP [50,51] and RDP [52]. Two major spleen preserving surgical techniques have been described in the literature, the Warshaw method [53] and the Kimura [48] method. Warshaw's method consists of the ligation of the splenic vessels and the preservation of the left gastroepiploic artery and short gastric vessels while Kimura's method maintains splenic vascularization by preserving the splenic vessels.

The results of the current meta-analysis support the previously published evidence that RDP results in higher rates of spleen preservation when compared to the LDP.

Open conversion of MIS increases the length of the procedure and is associated with multiple complications. A variety of factors influence the surgeons' decision to convert an operation, amongst them bleeding, adhesions and insufficient visualization of important structures [54,55]. Several predictive factors for open conversion of minimally invasive distal pancreatectomy have been proposed and surgeons should keep them in mind when assessing patients for their eligibility for minimally invasive surgery (MIS). These include chronic pancreatitis, large malignant neoplasms, higher BMI, low serum albumin and smoking [56].

The rate of open conversion in this current study was greater in the LDP group. This difference might be attributed to the better field visualization and increased range of motion provided by the robot [56,57].

Intraoperative blood loss is associated with an increased risk of complications [58], while blood transfusion during surgery for malignancies is connected to an elevated relapse risk [59]. Both parameters were found to be equal in the LDP and RDP groups.

POPF remains one of the most significant complications after pancreatic surgery [60], as it can lead to the development of an abscess, a pseudoaneurysm and even sepsis [61,62]. It is a relatively common complication of peripheral pancreatectomy as it is reported in up to 60% of the cases [63].

The pathogenetic mechanism of fistula formation is closely linked to intraoperative damage to the major or accessory pancreatic ducts and anastomotic leakage [63]. A recent meta-analysis on the risk factors for the formation of POPF after distal pancreatectomy concluded that patients with low pancreatic tissue density, high BMI, considerable intraoperative blood loss and blood transfusion, as well as those that underwent longer operations are more susceptible to POPF development [64]. Interestingly, several authors report young age [65,66] and splenectomy [12,67] as risk factors.

Multiple intraoperative and perioperative interventions, such as various stump closure methods, somatostatin analogs administration and earlier intraperitoneal drain removal, have been proposed to reduce the rates of POPF. None has been established as the gold-standard due to the lack of statistically significant evidence [68].

The implementation of MIS has been also studied as a potential way to reduce the rates of POPF, but no significant difference has been reported when comparing open pancreatectomy versus LDP versus RDP, even though RDP results in higher rates of spleen preservation [13,69,70].

In line with results from the existing literature, the current study reports no difference in POPF occurrence when comparing LDP and RDP.

Overall morbidity as well as individual postoperative variables, such as severe complications (Clavien-Dindo \geq 3) fluid collections, postoperative hemorrhage, SSI, reoperation, readmission and mortality, were found to be equal in the LDP and RDP groups.

In this study, no difference was noted between LDP and RDP groups regarding positive resection margins, while greater yield of lymph nodes was found in the RDP group.

It is widely known in the surgical oncology community that R0 resection in pancreatic cancer, defined as complete resection of the tumor with negative resection margins as determined by histopathology, is associated with better median survival time and 5-year survival rate [71-73]. Lymph node pathologic examination is an integral part of disease staging for pancreatic cancer [74]. As a consequence, the number of lymph nodes that the surgeon can harvest during surgery is an important tool to assess the effectiveness of the surgical method implemented.

As LDP has been previously found to be equally effective with open distal pancreatectomy in regards to R0 resection and lymph node yield [75], we can conclude that RDP can be effectively and safely implemented in pancreatic cancer care by experienced surgeons.

One of the most important advantages of MIS is shorter time needed for recovery [65]. Thus, evaluation of the LOS is an important parameter when analyzing such procedures. In the current study, LOS was significantly shorter in the RDP group. This could be an argument in favor of the robot when considering the overall cost effective-ness [13].

Robotic MIS has always been considered more costly than its laparoscopic counterpart [76], but data addressing cost-effectiveness specifically for RDP are not widely available. The majority of the studies on the subject report significantly higher operative cost for the robotic group when comparing RDP with LDP [13,31,42,77]. On the other hand, some authors argue that when total hospitalization costs are taken into consideration RDP seems to be as cost-effective as LDP [42,77].

This meta-analysis found that RDP is not only associated with higher operative costs but also with higher total hospitalization costs.

The present meta-analysis had some limitations that should be taken into consideration. Importantly, most of the studies included were nonrandomized and the majority were retrospective in their design, thus potentially introducing some selection bias. Furthermore, we only included studies written in English and as a result, we may have excluded possibly relevant studies written in other languages. Finally, heterogeneity was high in most of the analyses performed.

To conclude, this meta-analysis demonstrates the potential of RDP to become a widespread, viable option for both benign and malignant pancreatic disorders. Further investigation through multicentric Randomized Controlled Trials is needed to conclusively assess the safety and feasibility of RDP.

Conflict of interests

The authors declare no conflict of interests.

References

- Fernández-Cruz L. Distal pancreatic resection: technical differences between open and laparoscopic approaches. HPB (Oxford) 2006;8:49-56. https://doi.org/10.1080/13651820500468059.
- Cuschieri A, Jakimowicz JJ, van Spreeuwel J. Laparoscopic distal 70% pancreatectomy and splenectomy for chronic pancreatitis. Ann Surg 1996;223:280-5. https:// doi.org/10.1097/00000658-199603000-00008.
- Gagner M, Pomp A, Herrera MF. Early experience with laparoscopic resections of islet cell tumors. Surgery 1996;120:1051-4. https://doi.org/10.1016/s0039-6060(96)80054-7.
- Fingerhut A, Uranues S, Khatkov I, Boni L. Laparoscopic distal pancreatectomy: better than open? Transl Gastroenterol Hepatol 2018;3. https://doi.org/10.21037/ tgh.2018.07.04.
- Jusoh AC, Ammori BJ. Laparoscopic versus open distal pancreatectomy: a systematic review of comparative studies. Surg Endosc 2012;26:904-13. https://doi. org/10.1007/s00464-011-2016-3.
- Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg 2012;255:1048-59. https:// doi.org/10.1097/SLA.0b013e318251ee09.
- Melvin WS, Needleman BJ, Krause KR, Ellison EC. Robotic resection of pancreatic neuroendocrine tumor. J Laparoendosc Adv Surg Tech A 2003;13:33-6. https:// doi.org/10.1089/109264203321235449.
- Cirocchi R, Partelli S, Coratti A, Desiderio J, Parisi A, Falconi M. Current status of robotic distal pancreatectomy: a systematic review. Surg Oncol 2013;22:201-7. https://doi.org/10.1016/j.suronc.2013.07.002.
- 9. Jung MK, Buchs NC, Azagury DE, Hagen ME, Morel P. Robotic distal pancreatectomy: a valid option? Minerva Chir 2013;68:489-97.
- 10. Magge D, Zureikat A, Hogg M, Zeh HJ. Minimally Invasive Approaches to Pancreatic Surgery. Surg Oncol

Clin N Am 2016;25:273-86. https://doi.org/10.1016/j. soc.2015.11.001.

- 11. Xie K, Zhu Y-P, Xu X-W, Chen K, Yan J-F, Mou Y-P. Laparoscopic distal pancreatectomy is as safe and feasible as open procedure: A meta-analysis. World J Gastroenterol 2012;18:1959-67. https://doi.org/10.3748/wjg. v18.i16.1959.
- 12. Kleeff J, Diener MK, Z'graggen K et al. Distal Pancreatectomy. Ann Surg 2007;245:573-82. https://doi. org/10.1097/01.sla.0000251438.43135.fb.
- Guerrini GP, Lauretta A, Belluco C et al. Robotic versus laparoscopic distal pancreatectomy: an up-to-date meta-analysis. BMC Surg 2017;17:105. https://doi. org/10.1186/s12893-017-0301-3.
- 14. Bassi C, Dervenis C, Butturini G et al. Postoperative pancreatic fistula: An international study group (IS-GPF) definition. Surgery 2005;138:8-13. https://doi.org/10.1016/j.surg.2005.05.001.
- Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery 2004;240:205-13. https://doi. org/10.1097/01.SLA.0000133083.54934.AE.
- 16. Wells GA, Shea B, O'connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Department of Epidemiology and Community Medicine, University of Ottawa, Canada. University of Ottawa, Canada: Available at: Www Ohri ca/Programs/Clinical_epidemiology/Oxford Asp 2011.
- 17. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 2005;5:13. https://doi.org/10.1186/1471-2288-5-13.
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine 2009;6:e1000097. https://doi.org/10.1371/journal. pmed.1000097.

- Ryan CE, Ross SB, Sukharamwala PB, Sadowitz BD, Wood TW, Rosemurgy AS. Distal pancreatectomy and splenectomy: a robotic or LESS approach. JSLS 2015;19:e2014.00246. https://doi.org/10.4293/ JSLS.2014.00246.
- Han HJ, Kang CM. Reduced port minimally invasive distal pancreatectomy: single-port laparoscopic versus robotic single-site plus one-port distal pancreatectomy. Surg Endosc 2019;33:1091-9. https://doi.org/10.1007/ s00464-018-6361-3.
- 21. Ielpo B, Duran H, Diaz E et al. Robotic versus laparoscopic distal pancreatectomy: A comparative study of clinical outcomes and costs analysis. Int J Surg 2017;48:300-4. https://doi.org/10.1016/j.ijsu.2017.10.075.
- Adam MA, Choudhury K, Goffredo P et al. Minimally Invasive Distal Pancreatectomy for Cancer: Short-Term Oncologic Outcomes in 1,733 Patients. World Journal of Surgery 2015;39:2564-72. https://doi.org/10.1007/ s00268-015-3138-x.
- Balzano G, Bissolati M, Boggi U, Bassi C, Zerbi A, Falconi M. A multicenter survey on distal pancreatectomy in Italy: results of minimally invasive technique and variability of perioperative pathways. Updates in Surgery 2014;66:253-63. https://doi.org/10.1007/s13304-014-0273-0.
- 24. Benizri EI, Germain A, Ayav A et al. Short-term perioperative outcomes after robot-assisted and laparoscopic distal pancreatectomy. Journal of Robotic Surgery 2014;8:125-32. https://doi.org/10.1007/s11701-013-0438-8.
- Daouadi M, Zureikat AH, Zenati MS et al. Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg 2013;257:128-32. https://doi.org/10.1097/SLA.0b013e31825fff08.
- 26. Duran H, Ielpo B, Caruso R et al. Does robotic distal pancreatectomy surgery offer similar results as laparoscopic and open approach? A comparative study from a single medical center. Int J Medical Robotics + Computer Assisted Surgery : MRCAS 2014;10:280-5. https:// doi.org/10.1002/rcs.1569.
- Eckhardt S, Schicker C, Maurer E, Fendrich V, Bartsch DK. Robotic-Assisted Approach Improves Vessel Preservation in Spleen-Preserving Distal Pancreatectomy. Digestive Surgery 2016;33:406-13. https://doi. org/10.1159/000444269.
- Fisher A V, Fernandes-Taylor S, Schumacher JR et al. Analysis of 90-day cost for open versus minimally invasive distal pancreatectomy. HPB : The Official Journal of the International Hepato Pancreato Biliary Association 2018. https://doi.org/10.1016/j.hpb.2018.07.003.
- 29. Goh BKP, Chan CY, Soh H-L et al. A comparison between robotic-assisted laparoscopic distal pancreatectomy versus laparoscopic distal pancreatectomy. Int J Medical Robotics + Computer Assisted Surgery : MRCAS 2017;13. https://doi.org/10.1002/rcs.1733.
- Ito M, Asano Y, Shimizu T, Uyama I, Horiguchi A. Comparison of standard laparoscopic distal pancreatectomy with minimally invasive distal pancreatectomy using the da Vinci S system. Hepato-Gastroenterology 2014;61:493-6.
- 31. Kang CM, Kim DH, Lee WJ, Chi HS. Conventional laparoscopic and robot-assisted spleen-preserving pan-

createctomy: does da Vinci have clinical advantages? Surg Endosc 2011;25:2004-9. https://doi.org/10.1007/ s00464-010-1504-1.

- 32. Lai ECH, Tang CN. Robotic distal pancreatectomy versus conventional laparoscopic distal pancreatectomy: a comparative study for short-term outcomes. Front Med 2015;9:356-60. https://doi.org/10.1007/s11684-015-0404-0.
- Lee SY, Allen PJ, Sadot E et al. Distal pancreatectomy: a single institution's experience in open, laparoscopic, and robotic approaches. J Am Coll Surgeons 2015;220:18-27. https://doi.org/10.1016/j.jamcollsurg.2014.10.004.
- Liu R, Liu Q, Zhao Z-M, Tan X-L, Gao Y-X, Zhao G-D. Robotic versus laparoscopic distal pancreatectomy: A propensity score-matched study. J Surg Oncol 2017;116:461-9. https://doi.org/10.1002/jso.24676.
- 35. Morelli L, Guadagni S, Palmeri M et al. A Case-Control Comparison of Surgical and Functional Outcomes of Robotic-Assisted Spleen-Preserving Left Side Pancreatectomy versus Pure Laparoscopy. J Pancreas 2016;17:30-5.
- Raoof M, Nota CLMA, Melstrom LG et al. Oncologic outcomes after robot-assisted versus laparoscopic distal pancreatectomy: Analysis of the National Cancer Database. J Surg Oncol 2018. https://doi.org/10.1002/ jso.25170.
- 37. Xourafas D, Ashley SW, Clancy TE. Comparison of Perioperative Outcomes between Open, Laparoscopic, and Robotic Distal Pancreatectomy: an Analysis of 1815 Patients from the ACS-NSQIP Procedure-Targeted Pancreatectomy Database. J Gastrointest Surg 2017;21:1442–52. https://doi.org/10.1007/s11605-017-3463-5.
- Zhang J, Jin J, Chen S et al. Minimally invasive distal pancreatectomy for PNETs: laparoscopic or robotic approach? Oncotarget 2017;8:33872-83. https://doi. org/10.18632/oncotarget.17513.
- 39. Butturini G, Damoli I, Crepaz L et al. A prospective non-randomised single-center study comparing laparoscopic and robotic distal pancreatectomy. Surg Endosc 2015;29:3163-70. https://doi.org/10.1007/s00464-014-4043-3.
- 40. Chen S, Zhan Q, Chen J et al. Robotic approach improves spleen-preserving rate and shortens postoperative hospital stay of laparoscopic distal pancreatectomy: a matched cohort study. Surg Endosc 2015;29:3507-18. https://doi.org/10.1007/s00464-015-4101-5.
- 41. Souche R, Herrero A, Bourel G et al. Robotic versus laparoscopic distal pancreatectomy: a French prospective single-center experience and cost-effectiveness analysis. Surg Endosc 2018;32:3562-9. https://doi.org/10.1007/s00464-018-6080-9.
- 42. Waters JA, Canal DF, Wiebke EA et al. Robotic distal pancreatectomy: cost effective? Surgery 2010;148:814-23. https://doi.org/10.1016/j.surg.2010.07.027.
- 43. Rondelli F, Balzarotti R, Villa F et al. Is robot-assisted laparoscopic right colectomy more effective than the conventional laparoscopic procedure? A meta-analysis of short-term outcomes. Int J Surg 2015;18:75-82. https://doi.org/10.1016/j.ijsu.2015.04.044.
- 44. Montalti R, Berardi G, Patriti A, Vivarelli M, Troisi RI.

Outcomes of robotic vs laparoscopic hepatectomy: A systematic review and meta-analysis. World J Gastroenterol 2015;21:8441-51. https://doi.org/10.3748/wjg. v21.i27.8441.

- 45. Xu S-B, Jia C-K, Wang J-R, Zhang R-C, Mou Y-P. Do patients benefit more from robot assisted approach than conventional laparoscopic distal pancreatectomy? A meta-analysis of perioperative and economic outcomes. J Formos Med Assoc 2019;118:268-78. https:// doi.org/10.1016/j.jfma.2018.05.003.
- 46. Kimura W, Yano M, Sugawara S et al. Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein: techniques and its significance. J Hepatobiliary Pancreat Sci 2010;17:813-23. https:// doi.org/10.1007/s00534-009-0250-z.
- 47. de Rooij T, Klompmaker S, Hilal MA, Kendrick ML, Busch OR, Besselink MG. Laparoscopic pancreatic surgery for benign and malignant disease. Nat Rev Gastroenterol Hepatol 2016;13:227-38. https://doi. org/10.1038/nrgastro.2016.17.
- Kimura W, Inoue T, Futakawa N, Shinkai H, Han I, Muto T. Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein. Surgery 1996;120:885-90. https://doi.org/10.1016/s0039-6060(96)80099-7.
- 49. Shoup M, Brennan MF, McWhite K, Leung DHY, Klimstra D, Conlon KC. The value of splenic preservation with distal pancreatectomy. Arch Surg 2002;137:164-8. https://doi.org/10.1001/archsurg.137.2.164.
- 50. Fernández-Cruz L, Martínez I, Gilabert R, Cesar-Borges G, Astudillo E, Navarro S. Laparoscopic distal pancreatectomy combined with preservation of the spleen for cystic neoplasms of the pancreas. J Gastrointest Surg 2004;8:493-501. https://doi.org/10.1016/j.gassur.2003.11.014.
- 51. Melotti G, Butturini G, Piccoli M et al. Laparoscopic Distal Pancreatectomy. Ann Surg 2007;246:77-82. https://doi.org/10.1097/01.sla.0000258607.17194.2b.
- Parisi A, Coratti F, Cirocchi R et al. Robotic distal pancreatectomy with or without preservation of spleen: a technical note. World J Surg Oncol 2014;12:295. https:// doi.org/10.1186/1477-7819-12-295.
- 53. Warshaw AL. Conservation of the spleen with distal pancreatectomy. Arch Surg 1988;123:550-3. https://doi. org/10.1001/archsurg.1988.01400290032004.
- Peters JH, Krailadsiri W, Incarbone R et al. Reasons for conversion from laparoscopic to open cholecystectomy in an urban teaching hospital. Am J Surg 1994;168:555-8; discussion 558-559. https://doi.org/10.1016/s0002-9610(05)80121-7.
- 55. Gheza F, Esposito S, Gruessner S, Mangano A, Fernandes E, Giulianotti PC. Reasons for open conversion in robotic liver surgery: A systematic review with pooled analysis of more than 1000 patients. Int J Med Robot 2019;15:e1976. https://doi.org/10.1002/rcs.1976.
- 56. Nassour I, Wang SC, Porembka MR et al. Conversion of Minimally Invasive Distal Pancreatectomy: Predictors and Outcomes. Ann Surg Oncol 2017;24:3725-31. https://doi.org/10.1245/s10434-017-6062-5.
- 57. 57. Nassour I, Polanco PM. Minimally Invasive Liver Surgery for Hepatic Colorectal Metastases. Curr

Colorectal Cancer Rep 2016;12:103-12. https://doi. org/10.1007/s11888-016-0316-7.

- 58. Malleo G, Salvia R, Mascetta G et al. Assessment of a complication risk score and study of complication profile in laparoscopic distal pancreatectomy. J Gastrointest Surg 2014;18:2009-15. https://doi.org/10.1007/ s11605-014-2651-9.
- 59. Partelli S, Cirocchi R, Randolph J, Parisi A, Coratti A, Falconi M. A systematic review and meta-analysis of spleen-preserving distal pancreatectomy with preservation or ligation of the splenic artery and vein. Surgeon 2016;14:109-18. https://doi.org/10.1016/j. surge.2015.11.002.
- 60. Kuroshima N, Tanaka T, Kuroki T et al. Triple-drug therapy to prevent pancreatic fistula after pancreatectomy in a rat model. Pancreatology 2016;16:917-21. https://doi.org/10.1016/j.pan.2016.06.011.
- 61. Fujii T, Nakao A, Murotani K et al. Influence of Food Intake on the Healing Process of Postoperative Pancreatic Fistula After Pancreatoduodenectomy: A Multi-institutional Randomized Controlled Trial. Ann Surg Oncol 2015;22:3905-12. https://doi.org/10.1245/s10434-015-4496-1.
- 62. Seetharam P, Rodrigues GS. Postoperative Pancreatic Fistula: A Surgeon's Nightmare! An Insight with a Detailed Literature Review. JOP 2015;16:115-24. https:// doi.org/10.6092/1590-8577/2937.
- Mech K, Wysocki Ł, Guzel T, Makiewicz M, Nyckowski P, Słodkowski M. A review of methods for preventing pancreatic fistula after distal pancreatectomy. Pol Przegl Chir 2018;90:38-44. https://doi. org/10.5604/01.3001.0011.7491.
- 64. Peng Y-P, Zhu X-L, Yin L-D et al. Risk factors of postoperative pancreatic fistula in patients after distal pancreatectomy: a systematic review and meta-analysis. Sci Rep 2017;7:185. https://doi.org/10.1038/s41598-017-00311-8.
- 65. Nakamura M, Nakashima H. Laparoscopic distal pancreatectomy and pancreatoduodenectomy: is it worthwhile? A meta-analysis of laparoscopic pancreatectomy. J Hepatobiliary Pancreat Sci 2013;20:421-8. https:// doi.org/10.1007/s00534-012-0578-7.
- 66. Yoshioka R, Saiura A, Koga R et al. Risk factors for clinical pancreatic fistula after distal pancreatectomy: analysis of consecutive 100 patients. World J Surg 2010;34:121-5. https://doi.org/10.1007/s00268-009-0300-3.
- 67. Goh BKP, Tan Y-M, Chung Y-FA et al. Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome, and management of the postoperative pancreatic fistula: a 21-year experience at a single institution. Arch Surg 2008;143:956-65. https://doi.org/10.1001/archsurg.143.10.956.
- 68. Kawaida H, Kono H, Hosomura N et al. Surgical techniques and postoperative management to prevent postoperative pancreatic fistula after pancreatic surgery. World J Gastroenterol 2019;25:3722-37. https://doi. org/10.3748/wjg.v25.i28.3722.
- 69. Senthilnathan P, Chinnusamy P, Ramanujam A et al. Comparison of Pathological Radicality between Open and Laparoscopic Pancreaticoduodenectomy in a Tertiary Centre. Indian J Surg Oncol 2015;6:20-5. https:// doi.org/10.1007/s13193-014-0372-x.

- 70. Gavriilidis P, Lim C, Menahem B, Lahat E, Salloum C, Azoulay D. Robotic versus laparoscopic distal pancreatectomy The first meta-analysis. HPB (Oxford) 2016;18:567-74. https://doi.org/10.1016/j. hpb.2016.04.008.
- 71. Konstantinidis IT, Warshaw AL, Allen JN et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg 2013;257:731-6. https://doi.org/10.1097/ SLA.0b013e318263da2f.
- Strobel O, Hank T, Hinz U et al. Pancreatic Cancer Surgery: The New R-status Counts. Ann Surg 2017;265:565-73. https://doi.org/10.1097/SLA.000000000001731.
- Yamamoto T, Uchida Y, Terajima H. Clinical impact of margin status on survival and recurrence pattern after curative-intent surgery for pancreatic cancer. Asian J Surg 2019;42:93-9. https://doi.org/10.1016/j. asjsur.2017.09.003.

- 74. Ashfaq A, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. J Gastrointest Surg 2014;18:1929-35. https://doi.org/10.1007/s11605-014-2566-5.
- 75. Ricci C, Casadei R, Taffurelli G et al. Laparoscopic versus open distal pancreatectomy for ductal adenocarcinoma: a systematic review and meta-analysis. J Gastrointest Surg 2015;19:770-81. https://doi.org/10.1007/ s11605-014-2721-z.
- Higgins RM, Frelich MJ, Bosler ME, Gould JC. Cost analysis of robotic versus laparoscopic general surgery procedures. Surg Endosc 2017;31:185-92. https://doi. org/10.1007/s00464-016-4954-2.
- 77. Rodriguez M, Memeo R, Leon P et al. Which method of distal pancreatectomy is cost-effective among open, laparoscopic, or robotic surgery? Hepatobiliary Surg Nutr 2018;7:345-52. https://doi.org/10.21037/ hbsn.2018.09.03.